<doc>
  <docmeta id="113hr1407rh">
    <bill congress="113" type="hr" number="1407" version="rh"/>
    <revision size="92374" annotations="0" status="complete" id="6" commit-time="2014-02-19T15:06:22Z" committer="mbohmer" doc="113hr1407rh/6.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Reported-in-House" bill-type="olc" dms-id="HF47D2515D4F744FD95CF09B98F7F9997" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 1407 RH: To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs.</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-09</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">IB</distribution-code>
		<calendar display="yes">Union Calendar No. 135</calendar>
		<congress display="yes">113th CONGRESS</congress>
		<session display="yes">1st Session</session>
		<legis-num>H. R. 1407</legis-num>
		<associated-doc display="yes" role="report">[Report No.
		  113–188]</associated-doc>
		<current-chamber display="yes">IN THE HOUSE OF
		  REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130409">April 9, 2013</action-date>
			<action-desc>
        <sponsor name-id="S000364">Mr. Shimkus</sponsor> (for
			 himself, <cosponsor name-id="G000562">Mr. Gardner</cosponsor>,
			 <cosponsor name-id="U000031">Mr. Upton</cosponsor>,
			 <cosponsor name-id="P000373">Mr. Pitts</cosponsor>,
			 <cosponsor name-id="W000215">Mr. Waxman</cosponsor>,
			 <cosponsor name-id="P000034">Mr. Pallone</cosponsor>,
			 <cosponsor name-id="B001248">Mr. Burgess</cosponsor>,
			 <cosponsor name-id="G000558">Mr. Guthrie</cosponsor>, and
			 <cosponsor name-id="K000378">Mr. Kinzinger of Illinois</cosponsor>) introduced
			 the following bill; which was referred to the
			 <committee-name added-display-style="italic" committee-id="HIF00" deleted-display-style="strikethrough">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<action>
			<action-date>August 2, 2013</action-date>
			<action-desc>Reported with amendments, committed to the Committee of
			 the Whole House on the State of the Union, and ordered to be
			 printed</action-desc>
			<action-instruction>Strike out all after the enacting clause and insert
			 the part printed in italic</action-instruction>
			<action-instruction>For text of introduced bill, see copy of bill as
			 introduced on April 9, 2013</action-instruction>
		</action>
		<action display="yes">
			<action-desc display="yes">
        <pagebreak/>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title display="yes">To amend the Federal Food, Drug, and
		  Cosmetic Act to reauthorize user fee programs relating to new animal
		  drugs.<pagebreak/>
    </official-title>
	</form>
	<legis-body changed="added" committee-id="HIF00" display-enacting-clause="yes-display-enacting-clause" id="H79985F532EF149B9A4B4A3B35FD17F54" reported-display-style="italic" style="OLC">
		<section id="HC1B45C56DC9E4AAA83E0BE7DCA371DFA" section-type="section-one">
      <enum>1.</enum>
      <header>Table of Contents</header>
			<toc changed="added" committee-id="HIF00" container-level="legis-body-container" lowest-bolded-level="division-lowest-bolded" lowest-level="section" quoted-block="no-quoted-block" regeneration="yes-regeneration" reported-display-style="italic">
				<toc-entry idref="HC1B45C56DC9E4AAA83E0BE7DCA371DFA" level="section">Sec. 1. Table of Contents.</toc-entry>
				<toc-entry idref="H697D085308F348A1A36267CB66E55E5E" level="title">Title I—Animal Drug User Fee
				Amendments</toc-entry>
				<toc-entry idref="H534BB7E90262469980D59FD394E3EE1E" level="section">Sec. 101. Short title; finding.</toc-entry>
				<toc-entry idref="H5B3A475902894FABB16F5CC1DA256C8D" level="section">Sec. 102. Definitions.</toc-entry>
				<toc-entry idref="HDFCACF2D7F6048B094CEE81934FFC369" level="section">Sec. 103. Authority to assess and use animal
				drug fees.</toc-entry>
				<toc-entry idref="H4B0D57F4F492484AB0026477B82E2463" level="section">Sec. 104. Reauthorization; reporting
				requirements.</toc-entry>
				<toc-entry idref="H0990EE7E1BA84E86963A121F3E3E804F" level="section">Sec. 105. Savings clause.</toc-entry>
				<toc-entry idref="H68DC208E871C4EE2BE4E11FC32B5AA99" level="section">Sec. 106. Effective date.</toc-entry>
				<toc-entry idref="H98B3FB34ADE143CB984081514FA7F305" level="section">Sec. 107. Sunset dates.</toc-entry>
				<toc-entry idref="HEBFF3B7325FF4C888B5E64EFD09FC9B8" level="title">Title II—Animal Generic Drug User Fee
				Amendments</toc-entry>
				<toc-entry idref="H264F43CF92334A8D98B1B02F32C4E877" level="section">Sec. 201. Short title; finding.</toc-entry>
				<toc-entry idref="H3E09AE53D7654C4EAE8B90062929F6ED" level="section">Sec. 202. Authority to assess and use generic
				new animal drug fees.</toc-entry>
				<toc-entry idref="HA2992BBB203C48F486BDBDF43BF9E1A0" level="section">Sec. 203. Reauthorization; reporting
				requirements.</toc-entry>
				<toc-entry idref="H83E3CC685FA74B32A47F803CED686D9C" level="section">Sec. 204. Savings clause.</toc-entry>
				<toc-entry idref="HC2BA9599B1D34A349F78F644EFB91691" level="section">Sec. 205. Effective date.</toc-entry>
				<toc-entry idref="HDD72B01819D14FAB84BD9832B4014201" level="section">Sec. 206. Sunset dates.</toc-entry>
			</toc>
		</section>
    <title id="H697D085308F348A1A36267CB66E55E5E">
      <enum>I</enum>
      <header>Animal Drug User Fee
			 Amendments</header>
			<section id="H534BB7E90262469980D59FD394E3EE1E">
        <enum>101.</enum>
        <header>Short title;
			 finding</header>
				<subsection id="H19F7F4F4EAE44A2FA9BBFDA7217BE46C">
          <enum>(a)</enum>
          <header>Short
			 title</header>
          <text>This title may be cited as the <quote>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Drug User Fee Amendments of 2013" proposed="true">Animal Drug User Fee
			 Amendments of 2013</cato:entity-ref>
            </quote>.</text>
				</subsection>
        <subsection id="HBB2F061037304EA2B8FBAB0048A4B6DC">
          <enum>(b)</enum>
          <header>Finding</header>
          <text>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> finds that the fees authorized by
			 the amendments made in this title will be dedicated toward expediting the
			 animal drug development process and the review of new and supplemental animal
			 drug applications and investigational animal drug submissions as set forth in
			 the goals identified, for purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4">part 4 of subchapter C of chapter VII of
			 the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, in the letters from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of
			 Health and Human Services</cato:entity-ref> to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Chairman of the Committee on Energy and
			 Commerce of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Chairman of the Committee on
			 Health, Education, Labor, and Pensions of the Senate</cato:entity-ref> as set forth in the
			 Congressional Record.</text>
				</subsection>
      </section>
      <section id="H5B3A475902894FABB16F5CC1DA256C8D">
        <enum>102.</enum>
        <header>Definitions</header>
        <text display-inline="no-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:739">Section 739 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">
              <cato:entity-ref entity-type="uscode" value="usc/21/379j–11">21 U.S.C. 379j–11</cato:entity-ref>
            </external-xref>)</cato:entity> is amended to read as follows:</text>
				<quoted-block changed="added" committee-id="HIF00" display-inline="no-display-inline" id="H08CD29B252824F06B9D1F6196E134B3C" reported-display-style="italic" style="OLC">
					<section id="HCFE2BEB930894E4E874A785E5D8C85F1">
            <enum>739.</enum>
            <header>Definitions</header>
            <text display-inline="no-display-inline">For purposes of this part:</text>
						<paragraph id="H72841A7FA7224BA981167715F095DA9A">
              <enum>(1)</enum>
              <text>The term <term>animal
				drug application</term> means an application for approval of any new animal
				drug submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:1">section 512(b)(1)</cato:entity-ref>. Such term does not include either a new
				animal drug application submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:2">section 512(b)(2)</cato:entity-ref> or a supplemental
				animal drug application.</text>
						</paragraph>
            <paragraph id="H5B36CF2EF2814ECDAD6DAD4BCCB10B77">
              <enum>(2)</enum>
              <text>The term
				<term>supplemental animal drug application</term> means—</text>
							<subparagraph id="H67207ACF5BD54016A1C1224D8AB8FD75">
                <enum>(A)</enum>
                <text>a request to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to approve a change in an animal drug application which has been
				approved; or</text>
							</subparagraph>
              <subparagraph id="H38C1282566EB4FE1B3998FDFB4C87265">
                <enum>(B)</enum>
                <text>a request to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to approve a change to an application approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:c/p:2">section
				512(c)(2)</cato:entity-ref> for which data with respect to safety or effectiveness are
				required.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H3012AC2010064EA0A024CF0D7F9DDC91">
              <enum>(3)</enum>
              <text>The term <term>animal
				drug product</term> means each specific strength or potency of a particular
				active ingredient or ingredients in final dosage form marketed by a particular
				manufacturer or distributor, which is uniquely identified by the labeler code
				and product code portions of the national drug code, and for which an animal
				drug application or a supplemental animal drug application has been
				approved.</text>
						</paragraph>
            <paragraph id="H62FBC692AA3E45318DEE2F8B29776C75">
              <enum>(4)</enum>
              <text>The term <term>animal
				drug establishment</term> means a foreign or domestic place of business which
				is at one general physical location consisting of one or more buildings all of
				which are within 5 miles of each other, at which one or more animal drug
				products are manufactured in final dosage form.</text>
						</paragraph>
            <paragraph id="H9B6AE47A48D44999AC2395BC04382949">
              <enum>(5)</enum>
              <text>The term
				<term>investigational animal drug submission</term> means—</text>
							<subparagraph id="H8772FDDCAA9C4C0C9C542C561C685DFD">
                <enum>(A)</enum>
                <text>the filing of a claim for
				an investigational exemption under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:j">section 512(j)</cato:entity-ref> for a new animal drug
				intended to be the subject of an animal drug application or a supplemental
				animal drug application; or</text>
							</subparagraph>
              <subparagraph id="HB0AA407498D34A86A1F2B5CC4CDB65AC">
                <enum>(B)</enum>
                <text>the submission of
				information for the purpose of enabling the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to evaluate the safety or
				effectiveness of an animal drug application or supplemental animal drug
				application in the event of their filing.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HFC1D062A9E56483DA1A651F836F6773F">
              <enum>(6)</enum>
              <text>The term <term>animal
				drug sponsor</term> means either an applicant named in an animal drug
				application that has not been withdrawn by the applicant and for which approval
				has not been withdrawn by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, or a person who has submitted an
				investigational animal drug submission that has not been terminated or
				otherwise rendered inactive by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="H922BD9429B85408A9E4CB31A4B3A5B44">
              <enum>(7)</enum>
              <text>The term <term>final
				dosage form</term> means, with respect to an animal drug product, a finished
				dosage form which is approved for administration to an animal without
				substantial further manufacturing. Such term includes animal drug products
				intended for mixing in animal feeds.</text>
						</paragraph>
            <paragraph id="HDD428FE76DF745EDA3AAF3545E4DF25E">
              <enum>(8)</enum>
              <text>The term <term>process
				for the review of animal drug applications</term> means the following
				activities of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> with respect to the review of animal drug
				applications, supplemental animal drug applications, and investigational animal
				drug submissions:</text>
							<subparagraph id="HCFF2CFEC753A493BBA32379ACA6D503F">
                <enum>(A)</enum>
                <text>The activities necessary
				for the review of animal drug applications, supplemental animal drug
				applications, and investigational animal drug submissions.</text>
							</subparagraph>
              <subparagraph id="H9C00610E60D64928A2CE2C0132A7B174">
                <enum>(B)</enum>
                <text>The issuance of action
				letters which approve animal drug applications or supplemental animal drug
				applications or which set forth in detail the specific deficiencies in animal
				drug applications, supplemental animal drug applications, or investigational
				animal drug submissions and, where appropriate, the actions necessary to place
				such applications, supplements, or submissions in condition for
				approval.</text>
							</subparagraph>
              <subparagraph id="HEDC5C3C043024C799AD79C23A7F6E1FD">
                <enum>(C)</enum>
                <text>The inspection of animal
				drug establishments and other facilities undertaken as part of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref>
				review of pending animal drug applications, supplemental animal drug
				applications, and investigational animal drug submissions.</text>
							</subparagraph>
              <subparagraph id="H93D6DFD06A73444186062A52BAF9AC79">
                <enum>(D)</enum>
                <text>Monitoring of research
				conducted in connection with the review of animal drug applications,
				supplemental animal drug applications, and investigational animal drug
				submissions.</text>
							</subparagraph>
              <subparagraph id="H3304768BB0C14C70AACE914839141F75">
                <enum>(E)</enum>
                <text>The development of
				regulations and policy related to the review of animal drug applications,
				supplemental animal drug applications, and investigational animal drug
				submissions.</text>
							</subparagraph>
              <subparagraph id="H169EA086BF7C46C2951F8227A6CD74DF">
                <enum>(F)</enum>
                <text>Development of standards
				for products subject to review.</text>
							</subparagraph>
              <subparagraph id="H4D70070D2599487A853C39210580C070">
                <enum>(G)</enum>
                <text>Meetings between the
				agency and the animal drug sponsor.</text>
							</subparagraph>
              <subparagraph id="HB411A53F48E84B7494C3488860E4A1CF">
                <enum>(H)</enum>
                <text>Review of advertising and
				labeling prior to approval of an animal drug application or supplemental animal
				drug application, but not after such application has been approved.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H21AE991D4F6B4947863C447E891BDEF5">
              <enum>(9)</enum>
              <text>The term <term>costs of
				resources allocated for the process for the review of animal drug
				applications</term> means the expenses in connection with the process for the
				review of animal drug applications for—</text>
							<subparagraph id="HC2416F08280D41B4A890F8B5720E3430">
                <enum>(A)</enum>
                <text>officers and employees of
				the Food and Drug Administration, contractors of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref>, advisory committees consulted with respect to the review of
				specific animal drug applications, supplemental animal drug applications, or
				investigational animal drug submissions, and costs related to such officers,
				employees, committees, and contractors, including costs for travel, education,
				and recruitment and other personnel activities;</text>
							</subparagraph>
              <subparagraph id="HF2EC813134644BBD85DF4ABEC535FB2A">
                <enum>(B)</enum>
                <text>management of information
				and the acquisition, maintenance, and repair of computer resources;</text>
							</subparagraph>
              <subparagraph id="HE196255E4A244651A82758FA9F071B78">
                <enum>(C)</enum>
                <text>leasing, maintenance,
				renovation, and repair of facilities and acquisition, maintenance, and repair
				of fixtures, furniture, scientific equipment, and other necessary materials and
				supplies; and</text>
							</subparagraph>
              <subparagraph id="HD0F72CA5605D4DFB8E8973A3C27E8E3F">
                <enum>(D)</enum>
                <text>collecting fees under
				section 740 and accounting for resources allocated for the review of animal
				drug applications, supplemental animal drug applications, and investigational
				animal drug submissions.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H98F70436D2DC4635BD39D61FF7F6D0E1">
              <enum>(10)</enum>
              <text>The term
				<term>adjustment factor</term> applicable to a fiscal year refers to the
				formula set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:8">section 735(8)</cato:entity-ref> with the base or comparator month being
				October 2002.</text>
						</paragraph>
            <paragraph id="H66FB90D37BF84C45824969FD6319C920">
              <enum>(11)</enum>
              <text>The term
				<term>person</term> includes an affiliate thereof.</text>
						</paragraph>
            <paragraph id="H4764C2B2F1FF473D900AAFB072773E5A">
              <enum>(12)</enum>
              <text>The term
				<term>affiliate</term> refers to the definition set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:11">section
				735(11)</cato:entity-ref>.</text>
						</paragraph>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section id="HDFCACF2D7F6048B094CEE81934FFC369">
        <enum>103.</enum>
        <header>Authority to assess
			 and use animal drug fees</header>
        <text display-inline="no-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740">Section 740 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">
              <cato:entity-ref entity-type="uscode" value="usc/21/379j–12">21 U.S.C. 379j–12</cato:entity-ref>
            </external-xref>)</cato:entity> is amended to read as follows:</text>
				<quoted-block changed="added" committee-id="HIF00" display-inline="no-display-inline" id="H79BED06A57FF40CB8CB754BCB8B18510" reported-display-style="italic" style="OLC">
					<section id="H31437D02B50A4F4E8B117D3885CFCAE0">
            <enum>740.</enum>
            <header>Authority to assess
				and use animal drug fees</header>
						<subsection id="HA500060558E449029404DCDEDAA6F590">
              <enum>(a)</enum>
              <header>Types of
				fees</header>
              <text>Beginning in fiscal year 2004, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall assess
				and collect fees in accordance with this section as follows:</text>
							<paragraph id="HAFC4DD877F7A465B80A89E1BE2D57F9C">
                <enum>(1)</enum>
                <header>Animal drug application
				and supplement fee</header>
								<subparagraph id="H2850F9F710D8430B8B73CD7881B3BF75">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Each person that submits, on or after September 1, 2003,
				an animal drug application or a supplemental animal drug application shall be
				subject to a fee as follows:</text>
									<clause id="H735AD4C0861645C7ACD1A9FE3A0A3D45">
                    <enum>(i)</enum>
                    <text>A
				fee established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref> for an animal drug application, except an
				animal drug application described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4">section 512(d)(4)</cato:entity-ref>.</text>
									</clause>
                  <clause id="H737F3F948E8C445EA40887FF388E39F0">
                    <enum>(ii)</enum>
                    <text>A fee established in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref>, in an amount that is equal to 50 percent of the amount of the
				fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref>, for—</text>
										<subclause id="H273038FD718B46A3AE48F9FE12CD8EE3">
                      <enum>(I)</enum>
                      <text>a supplemental animal
				drug application for which safety or effectiveness data are required;
				and</text>
										</subclause>
                    <subclause id="H96B6B53C489048C39FA3F3C65EBD9192">
                      <enum>(II)</enum>
                      <text>an animal drug
				application described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4">section 512(d)(4)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="H820161E5FAC549F4A0746E97DF9B54E8">
                  <enum>(B)</enum>
                  <header>Payment</header>
                  <text>The
				fee required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be due upon submission of the animal
				drug application or supplemental animal drug application.</text>
								</subparagraph>
                <subparagraph id="H34EFF852139440039EA055E7DA4337D9">
                  <enum>(C)</enum>
                  <header>Exception for
				previously filed application or supplement</header>
                  <text>If an animal drug
				application or a supplemental animal drug application was submitted by a person
				that paid the fee for such application or supplement, was accepted for filing,
				and was not approved or was withdrawn (without a waiver or refund), the
				submission of an animal drug application or a supplemental animal drug
				application for the same product by the same person (or the person’s licensee,
				assignee, or successor) shall not be subject to a fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph id="HCDD2A0B9DF4C4F2AB4ED5369C73ABB52">
                  <enum>(D)</enum>
                  <header>Refund of fee if
				application refused for filing</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall refund 75
				percent of the fee paid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> for any animal drug application
				or supplemental animal drug application which is refused for filing.</text>
								</subparagraph>
                <subparagraph id="H79692D35C8B246BEB86312EBDD1CD718">
                  <enum>(E)</enum>
                  <header>Refund of fee if
				application withdrawn</header>
                  <text>If an animal drug application or a
				supplemental animal drug application is withdrawn after the application or
				supplement was filed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may refund the fee or portion of the fee
				paid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> if no substantial work was performed on the
				application or supplement after the application or supplement was filed. The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall have the sole discretion to refund the fee under this
				paragraph. A determination by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> concerning a refund under this
				paragraph shall not be reviewable.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HBB47C4FFBC054D489B109123754F5FF3">
                <enum>(2)</enum>
                <header>Animal drug product
				fee</header>
								<subparagraph id="H1598BC7B740D4A6190E5D68A9FBDE55B">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Each person—</text>
									<clause id="H6518D012E896490F805EE65D48402448">
                    <enum>(i)</enum>
                    <text>who is named as the
				applicant in an animal drug application or supplemental animal drug application
				for an animal drug product which has been submitted for listing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section
				510</cato:entity-ref>; and</text>
									</clause>
                  <clause id="HF370DAF7DE8E4937A09E5209230C1C2B">
                    <enum>(ii)</enum>
                    <text>who, after September 1,
				2003, had pending before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an animal drug application or
				supplemental animal drug application,</text>
									</clause>
                  <continuation-text continuation-text-level="subparagraph">shall pay for each such animal drug
				product the annual fee established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</continuation-text>
                </subparagraph>
                <subparagraph id="H853BED0DBAE64E479AC75EE4361292FB">
                  <enum>(B)</enum>
                  <header>Payment; fee due
				date</header>
                  <text>Such fee shall be payable for the fiscal year in which the
				animal drug product is first submitted for listing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>, or is
				submitted for relisting under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> if the animal drug product has been
				withdrawn from listing and relisted. After such fee is paid for that fiscal
				year, such fee shall be due each subsequent fiscal year that the product
				remains listed, upon the later of—</text>
									<clause id="H6E72D5FD83FF45D7A7F6BEAA84FD730C">
                    <enum>(i)</enum>
                    <text>the first business day
				after the date of enactment of an appropriations Act providing for the
				collection and obligation of fees for such fiscal year under this section;
				or</text>
									</clause>
                  <clause id="HD8CA794722FD490890EB9707314CC307">
                    <enum>(ii)</enum>
                    <text>January 31 of each
				year.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HD4993A31BAEA49C7870972A2BEF8A741">
                  <enum>(C)</enum>
                  <header>Limitation</header>
                  <text>Such
				fee shall be paid only once for each animal drug product for a fiscal year in
				which the fee is payable.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H53572BC249F947B9B492210B5B001658">
                <enum>(3)</enum>
                <header>Animal drug
				establishment fee</header>
								<subparagraph id="H9C7A98F390794FD1B24B3912C1A8CAA7">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Each person—</text>
									<clause id="H9A20CCED3C6B4A6F8FBF53CD3410C996">
                    <enum>(i)</enum>
                    <text>who owns or operates,
				directly or through an affiliate, an animal drug establishment;</text>
									</clause>
                  <clause id="HA9854157557A43D8B0B03986F778B56F">
                    <enum>(ii)</enum>
                    <text>who is named as the
				applicant in an animal drug application or supplemental animal drug application
				for an animal drug product which has been submitted for listing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section
				510</cato:entity-ref>; and</text>
									</clause>
                  <clause id="HEDEE1677E51147C6B695ECFFFD3F974F">
                    <enum>(iii)</enum>
                    <text>who, after September 1,
				2003, had pending before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an animal drug application or
				supplemental animal drug application,</text>
									</clause>
                  <continuation-text continuation-text-level="subparagraph">shall be assessed an annual establishment
				fee as established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref> for each animal drug establishment listed
				in its approved animal drug application as an establishment that manufactures
				the animal drug product named in the application.</continuation-text>
                </subparagraph>
                <subparagraph id="HEED38BA79A5043AFBCBE58C755B068E2">
                  <enum>(B)</enum>
                  <header>Payment; fee due
				date</header>
                  <text>The annual establishment fee shall be assessed in each
				fiscal year in which the animal drug product named in the application is
				assessed a fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:2" proposed="true">paragraph (2)</cato:entity-ref> unless the animal drug establishment listed
				in the application does not engage in the manufacture of the animal drug
				product during the fiscal year. The fee under this paragraph for a fiscal year
				shall be due upon the later of—</text>
									<clause id="H1DF9B179D898447E934A27C4D6CDCA33">
                    <enum>(i)</enum>
                    <text>the first business day
				after the date of enactment of an appropriations Act providing for the
				collection and obligation of fees for such fiscal year under this section;
				or</text>
									</clause>
                  <clause id="H7F9C0189F8E2492F96107D98B721F5AA">
                    <enum>(ii)</enum>
                    <text>January 31 of each
				year.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H0FD52D0D896A4C308C99D125A53604A8">
                  <enum>(C)</enum>
                  <header>Limitation</header>
									<clause id="HD67E32A99E4C42DEADE5C2FFD14E3866">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>An establishment shall be assessed only one fee per
				fiscal year under this section, subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:3/sp:C/cl:ii" proposed="true">clause (ii)</cato:entity-ref>.</text>
									</clause>
                  <clause id="H9E9D0C33EE7F4783A12E8BB1E16E692B">
                    <enum>(ii)</enum>
                    <header>Certain
				manufacturers</header>
                    <text>If a single establishment manufactures both animal
				drug products and prescription drug products, as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:3">section 735(3)</cato:entity-ref>,
				such establishment shall be assessed both the animal drug establishment fee and
				the prescription drug establishment fee, as set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:736/ss:a/p:2">section 736(a)(2)</cato:entity-ref>,
				within a single fiscal year.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph id="H96BEDC6263A242F6A26F162823610EB0">
                <enum>(4)</enum>
                <header>Animal drug sponsor
				fee</header>
								<subparagraph id="H84D8FC635BEC4EF2A4C6B2F790C3E4C2">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Each person—</text>
									<clause id="H3ACBF72C32644CF394D3A67859B31208">
                    <enum>(i)</enum>
                    <text>who meets the definition
				of an animal drug sponsor within a fiscal year; and</text>
									</clause>
                  <clause id="H93EA6A384B1F435CBAAE9C56A4254218">
                    <enum>(ii)</enum>
                    <text>who, after September 1,
				2003, had pending before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an animal drug application, a
				supplemental animal drug application, or an investigational animal drug
				submission,</text>
									</clause>
                  <continuation-text continuation-text-level="subparagraph">shall be assessed an annual sponsor fee
				as established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</continuation-text>
                </subparagraph>
                <subparagraph id="H08F404279F9A4EFDA87778F7E6102562">
                  <enum>(B)</enum>
                  <header>Payment; fee due
				date</header>
                  <text>The fee under this paragraph for a fiscal year shall be due
				upon the later of—</text>
									<clause id="H6682DC03F7EC47DF813E90693F587C45">
                    <enum>(i)</enum>
                    <text>the first business day
				after the date of enactment of an appropriations Act providing for the
				collection and obligation of fees for such fiscal year under this section;
				or</text>
									</clause>
                  <clause id="HDD2D786087D241B5B38410C17DFF4EA4">
                    <enum>(ii)</enum>
                    <text>January 31 of each
				year.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H89FDF3A3BC14492F84D7935DFA33B095">
                  <enum>(C)</enum>
                  <header>Limitation</header>
                  <text>Each
				animal drug sponsor shall pay only one such fee each fiscal year.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HE6E8954D05A2485F8082D787B0B6984E">
              <enum>(b)</enum>
              <header>Fee revenue
				amounts</header>
							<paragraph id="H782EC3137BF84CFEAFA14576F18EA30E">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsections (c)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d" proposed="true">(d)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:f" proposed="true">(f)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g" proposed="true">(g)</cato:entity-ref>—</text>
								<subparagraph id="H9D6139286D7D4A2FB5BA1B9308963BF8">
                  <enum>(A)</enum>
                  <text>for fiscal year 2014, the
				fees required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be established to generate a total
				revenue amount of $23,600,000; and</text>
								</subparagraph>
                <subparagraph id="HB7141A84282D44B8BB0CA5AE97C7618A">
                  <enum>(B)</enum>
                  <text>for each of fiscal years
				2015 through 2018, the fees required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be established
				to generate a total revenue amount of $21,600,000.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H5A250AFDF60E4E0894A80D655A7D3ABC">
                <enum>(2)</enum>
                <header>Types of
				fees</header>
                <text>Of the total revenue amount determined for a fiscal year
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>—</text>
								<subparagraph id="H43EE68EE8219495B8BA2BB36EC70E11B">
                  <enum>(A)</enum>
                  <text>20 percent shall be
				derived from fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref> (relating to animal drug applications
				and supplements);</text>
								</subparagraph>
                <subparagraph id="H2EEA54B8435E4ABD915A162B006359C4">
                  <enum>(B)</enum>
                  <text>27 percent shall be
				derived from fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:2" proposed="true">subsection (a)(2)</cato:entity-ref> (relating to animal drug
				products);</text>
								</subparagraph>
                <subparagraph id="HB302CBF46F1145648082BAAC189FD9EB">
                  <enum>(C)</enum>
                  <text>26 percent shall be
				derived from fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:3" proposed="true">subsection (a)(3)</cato:entity-ref> (relating to animal drug
				establishments); and</text>
								</subparagraph>
                <subparagraph id="H86D0B49326594462BB4D8FCDE95B5E66">
                  <enum>(D)</enum>
                  <text>27 percent shall be
				derived from fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a/p:4" proposed="true">subsection (a)(4)</cato:entity-ref> (relating to animal drug
				sponsors).</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="H35A84DD218D347A496797A4F650EAC45">
              <enum>(c)</enum>
              <header>Annual fee setting;
				adjustments</header>
							<paragraph id="H582AF305DD214DDA87329EA5BD6E21F0">
                <enum>(1)</enum>
                <header>Annual fee
				setting</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish, 60 days before the start
				of each fiscal year beginning after September 30, 2003, for that fiscal year,
				animal drug application fees, supplemental animal drug application fees, animal
				drug sponsor fees, animal drug establishment fees, and animal drug product fees
				based on the revenue amounts established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref> and the
				adjustments provided under this subsection.</text>
							</paragraph>
              <paragraph id="H342468B164FB4AA987729089013493EA">
                <enum>(2)</enum>
                <header>Inflation
				adjustment</header>
                <text>For fiscal year 2015 and subsequent fiscal years, the
				revenue amounts established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref> shall be adjusted by the
				Secretary by notice, published in the Federal Register, for a fiscal year, by
				an amount equal to the sum of—</text>
								<subparagraph id="HC8D1B5EAAC7546CD8EA25976FDA23230">
                  <enum>(A)</enum>
                  <text>one;</text>
								</subparagraph>
                <subparagraph id="HF7D77472C251432EBB462EF9831AFD9C">
                  <enum>(B)</enum>
                  <text>the average annual
				percent change in the cost, per full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
				Drug Administration</cato:entity-ref>, of all personnel compensation and benefits paid with
				respect to such positions for the first 3 of the preceding 4 fiscal years for
				which data are available, multiplied by the average proportion of personnel
				compensation and benefits costs to total <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> costs for
				the first 3 years of the preceding 4 fiscal years for which data are available;
				and</text>
								</subparagraph>
                <subparagraph id="H8B14B37F900646528DBB5F97CD648550">
                  <enum>(C)</enum>
                  <text>the average annual
				percent change that occurred in the Consumer Price Index for urban consumers
				(Washington-Baltimore, DC-MD-VA-WV; not seasonally adjusted; all items less
				food and energy; annual index) for the first 3 years of the preceding 4 years
				for which data are available multiplied by the average proportion of all costs
				other than personnel compensation and benefits costs to total <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref> costs for the first 3 years of the preceding 4 fiscal years for
				which data are available.</text>
								</subparagraph>
                <continuation-text continuation-text-level="paragraph">The
				adjustment made each fiscal year under this paragraph shall be added on a
				compounded basis to the sum of all adjustments made each fiscal year after
				fiscal year 2014 under this paragraph.</continuation-text>
              </paragraph>
              <paragraph id="HFF4F6E62121C4CD496EDB2116B07B92A">
                <enum>(3)</enum>
                <header>Workload
				adjustment</header>
                <text>For fiscal year 2015 and subsequent fiscal years,
				after the revenue amounts established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref> are adjusted for
				inflation in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c/p:2" proposed="true">paragraph (2)</cato:entity-ref>, the revenue amounts shall be
				further adjusted for such fiscal year to reflect changes in the workload of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for the process for the review of animal drug applications. With
				respect to such adjustment—</text>
								<subparagraph id="H260E2FB9105C42A78F3D8771E766D284">
                  <enum>(A)</enum>
                  <text>such adjustment shall be
				determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> based on a weighted average of the change in the
				total number of animal drug applications, supplemental animal drug applications
				for which data with respect to safety or effectiveness are required,
				manufacturing supplemental animal drug applications, investigational animal
				drug study submissions, and investigational animal drug protocol submissions
				submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="H483CF1E01BC94B68AA324C999B1FD47C">
                  <enum>(B)</enum>
                  <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				publish in the Federal Register the fees resulting from such adjustment and the
				supporting methodologies; and</text>
								</subparagraph>
                <subparagraph id="H14AB7745E5E34BB9A2D657A1F371F68B">
                  <enum>(C)</enum>
                  <text>under no circumstances
				shall such adjustment result in fee revenues for a fiscal year that are less
				than the fee revenues for that fiscal year established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref>, as
				adjusted for inflation under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c/p:2" proposed="true">paragraph (2)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HE56A76CC17094266BC4EB44D4CD931FB">
                <enum>(4)</enum>
                <header>Final year
				adjustment</header>
                <text>For fiscal year 2018, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may, in addition
				to other adjustments under this subsection, further increase the fees under
				this section, if such an adjustment is necessary to provide for up to 3 months
				of operating reserves of carryover user fees for the process for the review of
				animal drug applications for the first 3 months of fiscal year 2019. If the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> has carryover balances for the process for the
				review of animal drug applications in excess of 3 months of such operating
				reserves, then this adjustment will not be made. If this adjustment is
				necessary, then the rationale for the amount of the increase shall be contained
				in the annual notice setting fees for fiscal year 2018.</text>
							</paragraph>
              <paragraph id="HEE7B57306E2845E4B70762202DE653F5">
                <enum>(5)</enum>
                <header>Limit</header>
                <text>The
				total amount of fees charged, as adjusted under this subsection, for a fiscal
				year may not exceed the total costs for such fiscal year for the resources
				allocated for the process for the review of animal drug applications.</text>
							</paragraph>
            </subsection>
            <subsection id="HA6BD17F5C24F4037A80481D67797C5EE">
              <enum>(d)</enum>
              <header>Fee waiver or
				reduction</header>
							<paragraph id="H13739E0E138F46AB8753B7C68DF227FA">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall grant a waiver from or a reduction of
				one or more fees assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds
				that—</text>
								<subparagraph id="HB67B7B0052F54B9EA93AFF6EA4AE1096">
                  <enum>(A)</enum>
                  <text>the assessment of the fee
				would present a significant barrier to innovation because of limited resources
				available to such person or other circumstances;</text>
								</subparagraph>
                <subparagraph id="H1CDDF0DAD4A04AB18EA2D30A1BFBF8D9">
                  <enum>(B)</enum>
                  <text>the fees to be paid by
				such person will exceed the anticipated present and future costs incurred by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in conducting the process for the review of animal drug
				applications for such person;</text>
								</subparagraph>
                <subparagraph id="H54C8C230684644D1A8A0F2F3846D70AE">
                  <enum>(C)</enum>
                  <text>the animal drug
				application or supplemental animal drug application is intended solely to
				provide for use of the animal drug in—</text>
									<clause id="H936444C56BC349A494A964947BCBE18B">
                    <enum>(i)</enum>
                    <text>a Type B medicated feed
				(as defined in <external-xref legal-doc="regulation" parsable-cite="cfr/21/558.3">section 558.3(b)(3)</external-xref> of title 21, Code of Federal Regulations (or
				any successor regulation)) intended for use in the manufacture of Type C
				free-choice medicated feeds; or</text>
									</clause>
                  <clause id="H686D711B269141DC84A1A4620F678751">
                    <enum>(ii)</enum>
                    <text>a Type C free-choice
				medicated feed (as defined in <external-xref legal-doc="usc" parsable-cite="usc/21/558">section 558.3(b)(4)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulation));</text>
									</clause>
                </subparagraph>
                <subparagraph id="H511E31AD18EE48F3A2D488D66734E415">
                  <enum>(D)</enum>
                  <text>the animal drug
				application or supplemental animal drug application is intended solely to
				provide for a minor use or minor species indication; or</text>
								</subparagraph>
                <subparagraph id="H35670E833EDB461494EAE4A93252ED4A">
                  <enum>(E)</enum>
                  <text>the sponsor involved is a
				small business submitting its first animal drug application to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				for review.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H92AD4E2F7C954D91BAFCABFA1DDE908E">
                <enum>(2)</enum>
                <header>Use of standard
				costs</header>
                <text>In making the finding in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d/p:1/sp:B" proposed="true">paragraph (1)(B)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				may use standard costs.</text>
							</paragraph>
              <paragraph id="HE5FCF679738C462CA1CF56F7635BEB9B">
                <enum>(3)</enum>
                <header>Rules for small
				businesses</header>
								<subparagraph id="H4EE3339060AD4901B1EDF7531D5E8574">
                  <enum>(A)</enum>
                  <header>Definition</header>
                  <text>In
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d/p:1/sp:E" proposed="true">paragraph (1)(E)</cato:entity-ref>, the term <term>small business</term> means an entity that has
				fewer than 500 employees, including employees of affiliates.</text>
								</subparagraph>
                <subparagraph id="HA5BB2BAA0F8043199DDAD70A7888309C">
                  <enum>(B)</enum>
                  <header>Waiver of application
				fee</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall waive under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d/p:1/sp:E" proposed="true">paragraph (1)(E)</cato:entity-ref> the
				application fee for the first animal drug application that a small business or
				its affiliate submits to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for review. After a small business or
				its affiliate is granted such a waiver, the small business or its affiliate
				shall pay application fees for all subsequent animal drug applications and
				supplemental animal drug applications for which safety or effectiveness data
				are required in the same manner as an entity that does not qualify as a small
				business.</text>
								</subparagraph>
                <subparagraph id="HB89DAA6396CA4E0E8B5AABFB95304C8A">
                  <enum>(C)</enum>
                  <header>Certification</header>
                  <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall require any person who applies for a waiver under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d/p:1/sp:E" proposed="true">paragraph
				(1)(E)</cato:entity-ref> to certify their qualification for the waiver. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				periodically publish in the Federal Register a list of persons making such
				certifications.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="H64213ABB1C9044E782562FA1727EA78A">
              <enum>(e)</enum>
              <header>Effect of failure To
				pay fees</header>
              <text>An animal drug application or supplemental
				animal drug application submitted by a person subject to fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection
				(a)</cato:entity-ref> shall be considered incomplete and shall not be accepted for filing by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> until all fees owed by such person have been paid. An investigational
				animal drug submission under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:739/p:5/sp:B">section 739(5)(B)</cato:entity-ref> that is submitted by a person
				subject to fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be considered incomplete and shall
				not be accepted for review by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> until all fees owed by such person
				have been paid. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may discontinue review of any animal drug
				application, supplemental animal drug application, or investigational animal
				drug submission from a person if such person has not submitted for payment all
				fees owed under this section by 30 days after the date upon which they are
				due.</text>
						</subsection>
            <subsection id="HC0BC07093B0B4034B5DB9DC2D4EDE704">
              <enum>(f)</enum>
              <header>Assessment of
				fees</header>
							<paragraph id="HEED8BE69DC9249EA89062123D765BE7B">
                <enum>(1)</enum>
                <header>Limitation</header>
                <text>Fees
				may not be assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> for a fiscal year beginning after
				fiscal year 2003 unless appropriations for salaries and expenses of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for such fiscal year (excluding the amount of fees
				appropriated for such fiscal year) are equal to or greater than the amount of
				appropriations for the salaries and expenses of the Food and Drug
				Administration for the fiscal year 2003 (excluding the amount of fees
				appropriated for such fiscal year) multiplied by the adjustment factor
				applicable to the fiscal year involved.</text>
							</paragraph>
              <paragraph id="H2C80F52B58874658B6394B9C395E54D5">
                <enum>(2)</enum>
                <header>Authority</header>
                <text>If
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not assess fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> during any portion of a
				fiscal year because of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref> and if at a later date in such fiscal year
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess such fees, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess and collect such
				fees, without any modification in the rate, for animal drug applications,
				supplemental animal drug applications, investigational animal drug submissions,
				animal drug sponsors, animal drug establishments, and animal drug products at
				any time in such fiscal year notwithstanding the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref>
				relating to the date fees are to be paid.</text>
							</paragraph>
            </subsection>
            <subsection id="H9ABB455980F84803861E6BBF43DA5913">
              <enum>(g)</enum>
              <header>Crediting and
				availability of fees</header>
							<paragraph id="H080F149F717E4031BA027C426B0717B9">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:C" proposed="true">paragraph (2)(C)</cato:entity-ref>, fees authorized under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be collected and available for obligation only to the
				extent and in the amount provided in advance in appropriations Acts. Such fees
				are authorized to be appropriated to remain available until expended. Such sums
				as may be necessary may be transferred from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>
				salaries and expenses appropriation account without fiscal year limitation to
				such appropriation account for salary and expenses with such fiscal year
				limitation. The sums transferred shall be available solely for the process for
				the review of animal drug applications.</text>
							</paragraph>
              <paragraph id="HA7FB552EED714EBE8A1337145757689E">
                <enum>(2)</enum>
                <header>Collections and
				appropriation acts</header>
								<subparagraph id="H9540E04251FB4AB5B552EE386D26BEC3">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The fees authorized by this section—</text>
									<clause id="H4062DD30087540068C483091E1FB031D">
                    <enum>(i)</enum>
                    <text>subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:C" proposed="true">subparagraph
				(C)</cato:entity-ref>, shall be collected and available in each fiscal year in an amount not to
				exceed the amount specified in appropriation Acts, or otherwise made available
				for obligation for such fiscal year; and</text>
									</clause>
                  <clause id="HD79E54220D0E438C89EBEC4AEEC735E5">
                    <enum>(ii)</enum>
                    <text>shall be available to
				defray increases in the costs of the resources allocated for the process for
				the review of animal drug applications (including increases in such costs for
				an additional number of full-time equivalent positions in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of
				Health and Human Services</cato:entity-ref> to be engaged in such process) over such costs,
				excluding costs paid from fees collected under this section, for fiscal year
				2003 multiplied by the adjustment factor.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H6696935B160646F5B5BC299C3B2FB755">
                  <enum>(B)</enum>
                  <header>Compliance</header>
                  <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be considered to have met the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph
				(A)(ii)</cato:entity-ref> in any fiscal year if the costs funded by appropriations and allocated
				for the process for the review of animal drug applications—</text>
									<clause id="H5AB30CE0C6E54EFF8AC54963A0881D38">
                    <enum>(i)</enum>
                    <text>are not more than 3
				percent below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>; or</text>
									</clause>
                  <clause id="HC880507E345D4C32A15AA4A3A3E9252E">
                    <enum>(ii)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="H6384908455BF4208A421F5B5CB8694FE">
                      <enum>(I)</enum>
                      <text>are more than 3 percent
				below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, and fees assessed for the
				fiscal year following the subsequent fiscal year are decreased by the amount in
				excess of 3 percent by which such costs fell below the level specified in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>; and</text>
										</subclause>
                    <subclause changed="added" committee-id="HIF00" id="H9DAA042F88B9494D915DAF7E5694CAC5" indent="up1" reported-display-style="italic">
                      <enum>(II)</enum>
                      <text>such costs are not more
				than 5 percent below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="HE9EEDBE528984E3FA254DF8C24EF2D58">
                  <enum>(C)</enum>
                  <header>Provision for early
				payments</header>
                  <text>Payment of fees authorized under this section for a
				fiscal year, prior to the due date for such fees, may be accepted by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in accordance with authority provided in advance in a prior year
				appropriations Act.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H40302893F1FC44E1BBF56B272466ECAF">
                <enum>(3)</enum>
                <header>Authorization of
				appropriations</header>
                <text>
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">For each of the fiscal years 2014 through 2018,
				<cato:property name="purpose">there is authorized to be appropriated for fees under this section</cato:property> <cato:funds-and-year amount="indefinite" year="2014, 2015, 2016, 2017, 2018">an amount
				equal to the total revenue amount determined under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:b" proposed="true">subsection (b)</cato:entity-ref> for the
				fiscal year, as adjusted or otherwise affected under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:c" proposed="true">subsection (c)</cato:entity-ref> and
				<cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:4" proposed="true">paragraph (4)</cato:entity-ref>
                    </cato:funds-and-year>.</cato:entity>
                </text>
							</paragraph>
              <paragraph id="H2820D0DF76774109BAE7466ACCF40E8C">
                <enum>(4)</enum>
                <header>Offset of
				overcollections; recovery of collection shortfalls</header>
								<subparagraph id="HCFDB581EDCDC41988A36527B1FD2804A">
                  <enum>(A)</enum>
                  <header>Offset of
				overcollections</header>
                  <text>If the sum of the cumulative amount of fees
				collected under this section for fiscal years 2014 through 2016 and the amount
				of fees estimated to be collected under this section for fiscal year 2017
				(including any increased fee collections attributable to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:4/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>),
				exceeds the cumulative amount appropriated pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref> for the
				fiscal years 2014 through 2017, the excess amount shall be credited to the
				appropriation account of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> as provided in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:1" proposed="true">paragraph (1)</cato:entity-ref>, and shall be subtracted from the amount of fees that would
				otherwise be authorized to be collected under this section pursuant to
				appropriation Acts for fiscal year 2018.</text>
								</subparagraph>
                <subparagraph id="HBAD65866F630456EBD19B6C32E2085F4">
                  <enum>(B)</enum>
                  <header>Recovery of collection
				shortfalls</header>
									<clause id="H566512AB0CEB46FD8940237BC14F63C1">
                    <enum>(i)</enum>
                    <header>Fiscal year
				2016</header>
                    <text>For fiscal year 2016, the amount of fees otherwise
				authorized to be collected under this section shall be increased by the amount,
				if any, by which the amount collected under this section and appropriated for
				fiscal year 2014 falls below the amount of fees authorized for fiscal year 2014
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref>.</text>
									</clause>
                  <clause id="H8E773F6313A642C3A0E265C6373BB790">
                    <enum>(ii)</enum>
                    <header>Fiscal year
				2017</header>
                    <text>For fiscal year 2017, the amount of fees otherwise
				authorized to be collected under this section shall be increased by the amount,
				if any, by which the amount collected under this section and appropriated for
				fiscal year 2015 falls below the amount of fees authorized for fiscal year 2015
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref>.</text>
									</clause>
                  <clause id="HD5A9AFA1B5B94D9688DF83EACDBC77C9">
                    <enum>(iii)</enum>
                    <header>Fiscal year
				2018</header>
                    <text>For fiscal year 2018, the amount of fees otherwise
				authorized to be collected under this section (including any reduction in the
				authorized amount under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>), shall be increased by the cumulative
				amount, if any, by which the amount collected under this section and
				appropriated for fiscal years 2016 and 2017 (including estimated collections
				for fiscal year 2017) falls below the cumulative amount of fees authorized
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref> for fiscal years 2016 and 2017.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="H4EEFF5DF674648A484B299BFF5F9377D">
              <enum>(h)</enum>
              <header>Collection of unpaid
				fees</header>
              <text>In any case where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not receive payment of
				a fee assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref> within 30 days after it is due, such fee
				shall be treated as a claim of the United States Government subject to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States Code</cato:entity-ref>.</text>
						</subsection>
            <subsection id="H97FFE12AD7C74BFF95C773B4E10E5AFF">
              <enum>(i)</enum>
              <header>Written requests for
				waivers, reductions, and refunds</header>
              <text>To qualify for consideration for
				a waiver or reduction under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:d" proposed="true">subsection (d)</cato:entity-ref>, or for a refund of any fee
				collected in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740/ss:a" proposed="true">subsection (a)</cato:entity-ref>, a person shall submit to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a written request for such waiver, reduction, or refund not later
				than 180 days after such fee is due.</text>
						</subsection>
            <subsection id="HA69EE2B79432464F94DAF7118FAEE569">
              <enum>(j)</enum>
              <header>Construction</header>
              <text>This
				section may not be construed to require that the number of full-time equivalent
				positions in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref>, for officers,
				employees, and advisory committees not engaged in the process of the review of
				animal drug applications, be reduced to offset the number of officers,
				employees, and advisory committees so engaged.</text>
						</subsection>
            <subsection id="H198403CABCFE4992B2DAF581BD78C358">
              <enum>(k)</enum>
              <header>Abbreviated new animal
				drug applications</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
							<paragraph id="HCDCCD3965F6F4BEF84E7452470F2808E">
                <enum>(1)</enum>
                <text>to the extent
				practicable, segregate the review of abbreviated new animal drug applications
				from the process for the review of animal drug applications; and</text>
							</paragraph>
              <paragraph id="HBFD8240E38534E7FB1A4CACB35FE2159">
                <enum>(2)</enum>
                <text>adopt other
				administrative procedures to ensure that review times of abbreviated new animal
				drug applications do not increase from their current level due to activities
				under the user fee
				program.</text>
							</paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section id="H4B0D57F4F492484AB0026477B82E2463">
        <enum>104.</enum>
        <header>Reauthorization;
			 reporting requirements</header>
        <text display-inline="no-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A">Section
			 740A of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-13">
              <cato:entity-ref entity-type="uscode" value="usc/21/379j–13">21 U.S.C. 379j–13</cato:entity-ref>
            </external-xref>)</cato:entity> is amended
			 to read as follows:</text>
				<quoted-block changed="added" committee-id="HIF00" display-inline="no-display-inline" id="HC478B5E5BEDD4B4B96FA939FEE25AF2B" reported-display-style="italic" style="OLC">
					<section id="H42CF024851684B91B70104BD8AB19AB3">
            <enum>740A.</enum>
            <header>Reauthorization;
				reporting requirements</header>
						<subsection id="HCC616D0AEA22415DA5A02F578111E26B">
              <enum>(a)</enum>
              <header>Performance
				report</header>
              <text display-inline="yes-display-inline">Beginning with fiscal
				year 2014, not later than 120 days after the end of each fiscal year during
				which fees are collected under this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall prepare and
				submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of Representatives</cato:entity-ref>
				and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and Pensions of the Senate</cato:entity-ref> a
				report concerning the progress of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> in achieving
				the goals identified in the letters described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Drug User Fee Amendments of 2013/s:101/ss:b" proposed="true">section 101(b) of the Animal
				Drug User Fee Amendments of 2013</cato:entity-ref> toward expediting the animal drug development
				process and the review of the new and supplemental animal drug applications and
				investigational animal drug submissions during such fiscal year, the future
				plans of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> for meeting the goals, the review
				times for abbreviated new animal drug applications, and the administrative
				procedures adopted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> to ensure that review
				times for abbreviated new animal drug applications are not increased from their
				current level due to activities under the user fee program.</text>
						</subsection>
            <subsection id="H1316FAAB2BF34C6B8579A29F9CF6D5B2">
              <enum>(b)</enum>
              <header>Fiscal
				report</header>
              <text display-inline="yes-display-inline">Beginning with fiscal
				year 2014, not later than 120 days after the end of each fiscal year during
				which fees are collected under this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall prepare and
				submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of Representatives</cato:entity-ref>
				and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and Pensions of the Senate</cato:entity-ref> a
				report on the implementation of the authority for such fees during such fiscal
				year and the use, by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, of the fees collected
				during such fiscal year for which the report is made.</text>
						</subsection>
            <subsection id="H7A6A0C64BC2F4022828F268D5D2B5FE0">
              <enum>(c)</enum>
              <header>Public
				availability</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make the reports required under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:a" proposed="true">subsections (a)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:b" proposed="true">(b)</cato:entity-ref> available to the public on the Internet Web site of the
				Food and Drug Administration.</text>
						</subsection>
            <subsection id="H7A99EA3115AA416BBE00CD62928F6350">
              <enum>(d)</enum>
              <header>Reauthorization</header>
							<paragraph id="HEC3CB33BD01D415EA4D6444E580FB8E2">
                <enum>(1)</enum>
                <header>Consultation</header>
                <text>In
				developing recommendations to present to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> with respect to the
				goals, and plans for meeting the goals, for the process for the review of
				animal drug applications for the first 5 fiscal years after fiscal year 2018,
				and for the reauthorization of this part for such fiscal years, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall consult with—</text>
								<subparagraph commented="no" id="HD5AC860A85994475A4D0D998629F8290">
                  <enum>(A)</enum>
                  <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy
				and Commerce of the House of Representatives</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph commented="no" id="HD044F906A2734BA3B8E3F2F8B84C2FD3">
                  <enum>(B)</enum>
                  <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health,
				Education, Labor, and Pensions of the Senate</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="H490AD63C0C04453B98F943685AFDB45B">
                  <enum>(C)</enum>
                  <text>scientific and academic
				experts;</text>
								</subparagraph>
                <subparagraph id="HAE438C0F818149D0B636100855435B5E">
                  <enum>(D)</enum>
                  <text>veterinary
				professionals;</text>
								</subparagraph>
                <subparagraph id="H0316E15A48B54425B6A12D8A9A92F881">
                  <enum>(E)</enum>
                  <text>representatives of
				patient and consumer advocacy groups; and</text>
								</subparagraph>
                <subparagraph id="H45D1615C309B4E9D87FC20FF90039171">
                  <enum>(F)</enum>
                  <text>the regulated
				industry.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H8EA67A72F85547B7A28E4800C741EB30">
                <enum>(2)</enum>
                <header>Prior public
				input</header>
                <text>Prior to beginning negotiations with the regulated industry
				on the reauthorization of this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<subparagraph id="HB7C28E8CC4934829980F2FF88C64C135">
                  <enum>(A)</enum>
                  <text>publish a notice in the
				Federal Register requesting public input on the reauthorization;</text>
								</subparagraph>
                <subparagraph id="H6DEE873A3450455384396974C68B7637">
                  <enum>(B)</enum>
                  <text>hold a public meeting at
				which the public may present its views on the reauthorization, including
				specific suggestions for changes to the goals referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:a" proposed="true">subsection
				(a)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="H317F931FBE4846738DAA1F0C37A69487">
                  <enum>(C)</enum>
                  <text>provide a period of 30
				days after the public meeting to obtain written comments from the public
				suggesting changes to this part; and</text>
								</subparagraph>
                <subparagraph id="HDFF75E88BD574D0DA23B93300FD944A2">
                  <enum>(D)</enum>
                  <text>publish the comments on
				the Food and Drug Administration’s Internet Web site.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HF2B386603B3649D8BA6F6A0242FBBB4F">
                <enum>(3)</enum>
                <header>Periodic
				consultation</header>
                <text>Not less frequently than once every 4 months during
				negotiations with the regulated industry, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall hold discussions
				with representatives of veterinary, patient, and consumer advocacy groups to
				continue discussions of their views on the reauthorization and their
				suggestions for changes to this part as expressed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:2" proposed="true">paragraph (2)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H1184E001052C4FFFB12AC8E027FA5585">
                <enum>(4)</enum>
                <header>Public review of
				recommendations</header>
                <text>After negotiations with the regulated industry,
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<subparagraph id="H071B911562564FB7B3136B1CBC580F59">
                  <enum>(A)</enum>
                  <text>present the
				recommendations developed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> to the congressional committees
				specified in such paragraph;</text>
								</subparagraph>
                <subparagraph id="HAA9E4838F34E445A916B716C1EBA2815">
                  <enum>(B)</enum>
                  <text>publish such
				recommendations in the Federal Register;</text>
								</subparagraph>
                <subparagraph id="H11682AABE41F4726BBBDC084020B21CD">
                  <enum>(C)</enum>
                  <text>provide for a period of
				30 days for the public to provide written comments on such
				recommendations;</text>
								</subparagraph>
                <subparagraph id="HB1696A268D534001B1C0C55FB95B426E">
                  <enum>(D)</enum>
                  <text>hold a meeting at which
				the public may present its views on such recommendations; and</text>
								</subparagraph>
                <subparagraph id="H05751329D470478CBB48D7DCD205C761">
                  <enum>(E)</enum>
                  <text>after consideration of
				such public views and comments, revise such recommendations as
				necessary.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HC0408B947CB541A3BD2073711C0BC3E5">
                <enum>(5)</enum>
                <header>Transmittal of
				recommendations</header>
                <text>Not later than January 15, 2018, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall transmit to Congress the revised recommendations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:4" proposed="true">paragraph (4)</cato:entity-ref>, a
				summary of the views and comments received under such paragraph, and any
				changes made to the recommendations in response to such views and
				comments.</text>
							</paragraph>
              <paragraph id="HC798FA718A804B398943E7219DF9F0A4">
                <enum>(6)</enum>
                <header>Minutes of negotiation
				meetings</header>
								<subparagraph id="H99B8DA59C9974935A057E89FDE2024EF">
                  <enum>(A)</enum>
                  <header>Public
				availability</header>
                  <text display-inline="yes-display-inline">Before
				presenting the recommendations developed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:1..5" proposed="true">paragraphs (1) through (5)</cato:entity-ref> to
				Congress, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make publicly available, on the Internet Web site
				of the Food and Drug Administration, minutes of<cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <external-xref legal-doc="public-law" parsable-cite="pl/110/316">
                        <cato:entity-ref entity-type="public-law" value="public-law/110/316">Public Law 110–316</cato:entity-ref>
                      </external-xref> (<cato:entity-ref entity-type="statute-at-large" value="statute-at-large/122/3509">122 Stat.
				3509</cato:entity-ref>)</cato:entity>” all negotiation meetings conducted under this subsection between the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> and the regulated industry.</text>
								</subparagraph>
                <subparagraph id="H1ED37DEB8D1B48C3A0FD387F6E8F83BD">
                  <enum>(B)</enum>
                  <header>Content</header>
                  <text>The
				minutes described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A/ss:d/p:6/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall summarize any substantive
				proposal made by any party to the negotiations as well as significant
				controversies or differences of opinion during the negotiations and their
				resolution.</text>
								</subparagraph>
              </paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section id="H0990EE7E1BA84E86963A121F3E3E804F">
        <enum>105.</enum>
        <header>Savings
			 clause</header>
        <text display-inline="no-display-inline">Notwithstanding the
			 amendments made by this title, <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4">part 4 of subchapter C of chapter VII of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">
              <cato:entity-ref entity-type="uscode" value="usc/21/379j–11/etseq">21 U.S.C. 379j–11 et seq.</cato:entity-ref>
            </external-xref>)</cato:entity>, as in effect
			 on the day before the date of the enactment of this title, shall continue to be
			 in effect with respect to animal drug applications and supplemental animal drug
			 applications (as defined in such part as of such day) that on or after October
			 1, 2008, but before October 1, 2013, were accepted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
			 Administration</cato:entity-ref> for filing with respect to assessing and collecting any fee
			 required by such part for a fiscal year prior to fiscal year 2014.</text>
			</section>
      <section id="H68DC208E871C4EE2BE4E11FC32B5AA99">
        <enum>106.</enum>
        <header>Effective
			 date</header>
        <text display-inline="no-display-inline">The amendments made by
			 this title shall take effect on October 1, 2013, or the date of enactment of
			 this title, whichever is later, except that fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:4">part 4 of subchapter C
			 of chapter VII of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as amended by this
			 title, shall be assessed for all animal drug applications and supplemental
			 animal drug applications received on or after October 1, 2013, regardless of
			 the date of the enactment of this title.</text>
			</section>
      <section id="H98B3FB34ADE143CB984081514FA7F305">
        <enum>107.</enum>
        <header>Sunset dates</header>
				<subsection id="H31DD3BF3696B4D59AB9015877206C3C0">
          <enum>(a)</enum>
          <header>Authorization</header>
          <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740">Section
			 740 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">
                <cato:entity-ref entity-type="uscode" value="usc/21/379j–12">21 U.S.C. 379j–12</cato:entity-ref>
              </external-xref>)</cato:entity> shall cease
			 to be effective October 1, 2018.</text>
				</subsection>
        <subsection id="H149C580C57D0435FA5B39B2C35095F0B">
          <enum>(b)</enum>
          <header>Reporting
			 requirements</header>
          <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:740A">Section 740A of the Federal Food, Drug, and Cosmetic
			 Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-13">
                <cato:entity-ref entity-type="uscode" value="usc/21/379j–13">21 U.S.C. 379j–13</cato:entity-ref>
              </external-xref>)</cato:entity> shall cease to be effective January 31, 2019.</text>
				</subsection>
        <subsection id="H78D3CC7073B5433A9CE67A75E6774EF5">
          <enum>(c)</enum>
          <header>Previous sunset
			 provision</header>
					<paragraph id="H256BB840A1E149BB9554E8C34B88AC15">
            <enum>(1)</enum>
            <header>In
			 general</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Animal Drug User Fee Amendments of 2008/s:108">Section 108 of the Animal Drug User Fee Amendments of
			 2008</cato:entity-ref> (<external-xref legal-doc="public-law" parsable-cite="pl/110/316">
                  <cato:entity-ref entity-type="public-law" value="public-law/110/316">Public Law 110–316</cato:entity-ref>
                </external-xref>)</cato:entity> is repealed.</text>
					</paragraph>
          <paragraph id="HF8CF629D43804A43B4074B5ADF7509FD">
            <enum>(2)</enum>
            <header>Conforming
			 amendment</header>
            <text display-inline="yes-display-inline">
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="public-law" value="public-law/110/316">Public Law 110–316</cato:entity-ref>
			 (<cato:entity-ref entity-type="statute-at-large" value="statute-at-large/122/3509">122 Stat. 3509</cato:entity-ref>)</cato:entity> is amended in the table of contents in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Drug User Fee Amendments of 2008/s:1">section 1</cato:entity-ref>, by striking
			 the item relating to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Drug User Fee Amendments of 2008/s:108">section 108</cato:entity-ref>.</text>
					</paragraph>
        </subsection>
        <subsection commented="no" display-inline="no-display-inline" id="HFD82329351614A6C94079BC25B75CA37">
          <enum>(d)</enum>
          <header>Technical
			 clarification</header>
          <text>Effective November 18, 2003, <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Animal Drug User Fee Act of 2003/s:5">section 5 of the
			 Animal Drug User Fee Act of 2003</cato:entity-ref> (<external-xref legal-doc="public-law" parsable-cite="pl/108/130">
                <cato:entity-ref entity-type="public-law" value="public-law/108/130">Public Law 108–130</cato:entity-ref>
              </external-xref>)</cato:entity> is repealed.</text>
				</subsection>
      </section>
    </title>
    <title id="HEBFF3B7325FF4C888B5E64EFD09FC9B8">
      <enum>II</enum>
      <header>Animal Generic Drug User
			 Fee Amendments</header>
			<section id="H264F43CF92334A8D98B1B02F32C4E877" section-type="section-one">
        <enum>201.</enum>
        <header>Short title;
			 finding</header>
				<subsection id="H1383DF0B08D74394B2FB52CF72031AED">
          <enum>(a)</enum>
          <header>Short
			 title</header>
          <text>This title may be cited as the <quote>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Generic Drug User Fee Amendments of 2013" proposed="true">Animal Generic Drug
			 User Fee Amendments of 2013</cato:entity-ref>
            </quote>.</text>
				</subsection>
        <subsection commented="no" id="H96C2F49A68D543EDB6415BE06A705461">
          <enum>(b)</enum>
          <header>Finding</header>
          <text>The fees authorized by this title will be
			 dedicated toward expediting the generic new animal drug development process and
			 the review of abbreviated applications for generic new animal drugs,
			 supplemental abbreviated applications for generic new animal drugs, and
			 investigational submissions for generic new animal drugs as set forth in the
			 goals identified in the letters from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref>
			 to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Chairman of the Committee on Energy and Commerce of the House of
			 Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Chairman of the Committee on Health, Education, Labor,
			 and Pensions of the Senate</cato:entity-ref> as set forth in the Congressional Record.</text>
				</subsection>
      </section>
      <section id="H3E09AE53D7654C4EAE8B90062929F6ED">
        <enum>202.</enum>
        <header>Authority to assess
			 and use generic new animal drug fees</header>
        <text display-inline="no-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741">Section 741 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">
              <cato:entity-ref entity-type="uscode" value="usc/21/379j–21">21 U.S.C. 379j–21</cato:entity-ref>
            </external-xref>)</cato:entity> is amended to read as follows:</text>
				<quoted-block changed="added" committee-id="HIF00" display-inline="no-display-inline" id="HF99F54679BE14B7C8721C9C896AE8422" reported-display-style="italic" style="OLC">
					<section id="H65576A16FC5B4F5BA58D4CDC0F772E48">
            <enum>741.</enum>
            <header>Authority to assess
				and use generic new animal drug fees</header>
						<subsection id="H7EEC61DDC47B429986C4EB8ED2360D57">
              <enum>(a)</enum>
              <header>Types of
				fees</header>
              <text>Beginning with respect to fiscal year 2009, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall assess and collect fees in accordance with this section as
				follows:</text>
							<paragraph id="H8BC7B2B93423473298065C4FDBFF126B">
                <enum>(1)</enum>
                <header>Abbreviated application
				fee</header>
								<subparagraph id="HBC908D12D31045F2AC2BC4159DD45236">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Each person that submits, on or after July 1, 2008, an
				abbreviated application for a generic new animal drug shall be subject to a fee
				as established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref> for such an application.</text>
								</subparagraph>
                <subparagraph id="HA962123A7DD64F82A122C4F82D1B5567">
                  <enum>(B)</enum>
                  <header>Payment</header>
                  <text>The
				fee required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be due upon submission of the
				abbreviated application.</text>
								</subparagraph>
                <subparagraph id="H93C5714BFAC84DDE95129C2A91BAE77C">
                  <enum>(C)</enum>
                  <header>Exceptions</header>
									<clause id="H2E574013BF3A461180FF7AFE56908AB6">
                    <enum>(i)</enum>
                    <header>Previously filed
				application</header>
                    <text>If an abbreviated application was submitted by a
				person that paid the fee for such application, was accepted for filing, and was
				not approved or was withdrawn (without a waiver or refund), the submission of
				an abbreviated application for the same product by the same person (or the
				person’s licensee, assignee, or successor) shall not be subject to a fee under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
									</clause>
                  <clause id="HCEA535DC29EE4C54A637D84ABBB2BB16">
                    <enum>(ii)</enum>
                    <header>Certain abbreviated
				applications involving combination animal drugs</header>
                    <text>An
				abbreviated application for an animal drug described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:4">section 512(d)(4)</cato:entity-ref> and
				submitted on or after October 1, 2013, shall be subject to a fee equal to 50
				percent of the amount of the abbreviated application fee established in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H1E8ABE30E52E44EBA1EFDF13F10F9ED7">
                  <enum>(D)</enum>
                  <header>Refund of fee if
				application refused for filing</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall refund 75
				percent of the fee paid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> for any abbreviated application
				which is refused for filing.</text>
								</subparagraph>
                <subparagraph id="H0F64DC7E45AB4B599270C7230E19A4F4">
                  <enum>(E)</enum>
                  <header>Refund of fee if
				application withdrawn</header>
                  <text>If an abbreviated application is withdrawn
				after the application was filed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may refund the fee or portion of
				the fee paid under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> if no substantial work was performed on the
				application after the application was filed. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall have the sole
				discretion to refund the fee under this subparagraph. A determination by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> concerning a refund under this subparagraph shall not be
				reviewable.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HFD34B13C617549BFACC5DDC4F2B85FD5">
                <enum>(2)</enum>
                <header>Generic new animal drug
				product fee</header>
								<subparagraph id="H5054493581E4462D87FFFBC6E4E0A55B">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Each person—</text>
									<clause id="HD70D952523744CF1A8FD80E6A7FFA1BB">
                    <enum>(i)</enum>
                    <text>who is named as the
				applicant in an abbreviated application or supplemental abbreviated application
				for a generic new animal drug product which has been submitted for listing
				under section 510; and</text>
									</clause>
                  <clause id="HC966D800BE0645F79605A86BE9D66A67">
                    <enum>(ii)</enum>
                    <text>who, after September 1,
				2008, had pending before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an abbreviated application or
				supplemental abbreviated application,</text>
									</clause>
                  <continuation-text continuation-text-level="subparagraph">shall pay for each such generic new
				animal drug product the annual fee established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</continuation-text>
                </subparagraph>
                <subparagraph id="H3E0114D996C14181A4F8C5AC526ED610">
                  <enum>(B)</enum>
                  <header>Payment; fee due
				date</header>
                  <text>Such fee shall be payable for the fiscal year in which the
				generic new animal drug product is first submitted for listing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section
				510</cato:entity-ref>, or is submitted for relisting under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> if the generic new animal
				drug product has been withdrawn from listing and relisted. After such fee is
				paid for that fiscal year, such fee shall be due each subsequent fiscal year
				that the product remains listed, upon the later of—</text>
									<clause id="H6F9ABBB32EAB4210925CD0FE7C16CC76">
                    <enum>(i)</enum>
                    <text>the first business day
				after the date of enactment of an appropriations Act providing for the
				collection and obligation of fees for such fiscal year under this section;
				or</text>
									</clause>
                  <clause id="HD8B81772FE69493D9538181A60D81937">
                    <enum>(ii)</enum>
                    <text>January 31 of each
				year.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HF7886196915741009F8CE086000D79C5">
                  <enum>(C)</enum>
                  <header>Limitation</header>
                  <text>Such
				fee shall be paid only once for each generic new animal drug product for a
				fiscal year in which the fee is payable.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H0B8D6C49A736491B8D802EAB4597AC16">
                <enum>(3)</enum>
                <header>Generic new animal drug
				sponsor fee</header>
								<subparagraph id="H12FCFD407E654A12978811FBAB218C66">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Each person—</text>
									<clause id="HC4A5BF2C91DF4AFBB38C54CEF7A472DE">
                    <enum>(i)</enum>
                    <text>who meets the definition
				of a generic new animal drug sponsor within a fiscal year; and</text>
									</clause>
                  <clause id="H6718F668A5534B279021B4CCC48F4BB0">
                    <enum>(ii)</enum>
                    <text>who, after September 1,
				2008, had pending before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> an abbreviated application, a
				supplemental abbreviated application, or an investigational submission,</text>
									</clause>
                  <continuation-text continuation-text-level="subparagraph">shall be assessed an annual generic new
				animal drug sponsor fee as established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</continuation-text>
                </subparagraph>
                <subparagraph id="HFDAF3B794240405F84CF295A3E5FCC4D">
                  <enum>(B)</enum>
                  <header>Payment; fee due
				date</header>
                  <text>Such fee shall be due each fiscal year upon the later
				of—</text>
									<clause id="H95A6C0274D744193A68422BDA46D9A5A">
                    <enum>(i)</enum>
                    <text>the first business day
				after the date of enactment of an appropriations Act providing for the
				collection and obligation of fees for such fiscal year under this section;
				or</text>
									</clause>
                  <clause id="H35DEA4A3AD9A4F67878239C00AE710C8">
                    <enum>(ii)</enum>
                    <text>January 31 of each
				year.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HA95AA17C8C1D47BDBF948B59C1A70044">
                  <enum>(C)</enum>
                  <header>Amount of
				fee</header>
                  <text>Each generic new animal drug sponsor shall pay only 1 such
				fee each fiscal year, as follows:</text>
									<clause id="H8BC4FEE501044243AAC938ACAAFC6742">
                    <enum>(i)</enum>
                    <text>100 percent of the amount
				of the generic new animal drug sponsor fee published for that fiscal year under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref> for an applicant with more than 6 approved abbreviated
				applications.</text>
									</clause>
                  <clause id="H9C8258C52DBF479F8FBFF4FBC73E4C46">
                    <enum>(ii)</enum>
                    <text>75 percent of the amount
				of the generic new animal drug sponsor fee published for that fiscal year under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref> for an applicant with more than 1 and fewer than 7 approved
				abbreviated applications.</text>
									</clause>
                  <clause id="H0971EBBD9653465DA0ED721D8943F13A">
                    <enum>(iii)</enum>
                    <text>50 percent of the
				amount of the generic new animal drug sponsor fee published for that fiscal
				year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsection (c)</cato:entity-ref> for an applicant with 1 or fewer approved abbreviated
				applications.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HFF1C8B6668A04A51B4FB0C5A4429CD59">
              <enum>(b)</enum>
              <header>Fee
				amounts</header>
              <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:c" proposed="true">subsections (c)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:d" proposed="true">(d)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:f" proposed="true">(f)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g" proposed="true">(g)</cato:entity-ref>, the fees
				required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be established to generate fee revenue
				amounts as follows:</text>
							<paragraph id="H8454A6A807F34ECF8171190DBA8BAE83">
                <enum>(1)</enum>
                <header>Total fee revenues for
				application fees</header>
                <text>The total fee revenues to be collected in
				abbreviated application fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref> shall be $1,832,000 for
				fiscal year 2014, $1,736,000 for fiscal year 2015, $1,857,000 for fiscal year
				2016, $1,984,000 for fiscal year 2017, and $2,117,000 for fiscal year
				2018.</text>
							</paragraph>
              <paragraph id="HC3114FDD233448218F66F631DDF113DF">
                <enum>(2)</enum>
                <header>Total fee revenues for
				product fees</header>
                <text>The total fee revenues to be collected in generic
				new animal drug product fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:2" proposed="true">subsection (a)(2)</cato:entity-ref> shall be $2,748,000 for
				fiscal year 2014, $2,604,000 for fiscal year 2015, $2,786,000 for fiscal year
				2016, $2,976,000 for fiscal year 2017, and $3,175,000 for fiscal year
				2018.</text>
							</paragraph>
              <paragraph id="HBA7C3D3C1A9A48B78BE06DADA649C5AE">
                <enum>(3)</enum>
                <header>Total fee revenues for
				sponsor fees</header>
                <text>The total fee revenues to be collected in generic
				new animal drug sponsor fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a/p:3" proposed="true">subsection (a)(3)</cato:entity-ref> shall be $2,748,000 for
				fiscal year 2014, $2,604,000 for fiscal year 2015, $2,786,000 for fiscal year
				2016, $2,976,000 for fiscal year 2017, and $3,175,000 for fiscal year
				2018.</text>
							</paragraph>
            </subsection>
            <subsection id="H79422AEDC50B4550BED76882F9AE9F22">
              <enum>(c)</enum>
              <header>Annual fee setting;
				adjustments</header>
							<paragraph id="H305EAF44DFE144D4BB98715C3716B4B1">
                <enum>(1)</enum>
                <header>Annual fee
				setting</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish, 60 days before the start
				of each fiscal year beginning after September 30, 2008, for that fiscal year,
				abbreviated application fees, generic new animal drug sponsor fees, and generic
				new animal drug product fees, based on the revenue amounts established under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:b" proposed="true">subsection (b)</cato:entity-ref> and the adjustments provided under this subsection.</text>
							</paragraph>
              <paragraph id="HB602349E6295496DBE26DE41342519F7">
                <enum>(2)</enum>
                <header>Workload
				adjustment</header>
                <text>The fee revenues shall be adjusted each fiscal year
				after fiscal year 2014 to reflect changes in review workload. With respect to
				such adjustment:</text>
								<subparagraph id="H8742F207840C476B9887D2EE8C74DC88">
                  <enum>(A)</enum>
                  <text>This adjustment shall be
				determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> based on a weighted average of the change in the
				total number of abbreviated applications for generic new animal drugs,
				manufacturing supplemental abbreviated applications for generic new animal
				drugs, investigational generic new animal drug study submissions, and
				investigational generic new animal drug protocol submissions submitted to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish in the Federal Register the fees
				resulting from this adjustment and the supporting methodologies.</text>
								</subparagraph>
                <subparagraph id="H4D85D3E2BA8048EB91D780C0F5F86C5A">
                  <enum>(B)</enum>
                  <text>Under no circumstances
				shall this workload adjustment result in fee revenues for a fiscal year that
				are less than the fee revenues for that fiscal year established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:b" proposed="true">subsection
				(b)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HBDE6BB74CA9C4690AD48E07E6C331DF1">
                <enum>(3)</enum>
                <header>Final year
				adjustment</header>
                <text>For fiscal year 2018, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may, in addition
				to other adjustments under this subsection, further increase the fees under
				this section, if such an adjustment is necessary, to provide for up to 3 months
				of operating reserves of carryover user fees for the process for the review of
				abbreviated applications for generic new animal drugs for the first 3 months of
				fiscal year 2019. If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> has carryover balances
				for the process for the review of abbreviated applications for generic new
				animal drugs in excess of 3 months of such operating reserves, then this
				adjustment shall not be made. If this adjustment is necessary, then the
				rationale for the amount of the increase shall be contained in the annual
				notice setting fees for fiscal year 2018.</text>
							</paragraph>
              <paragraph id="HF27006639EFB4BDFB3474958C4F8D8F8">
                <enum>(4)</enum>
                <header>Limit</header>
                <text>The
				total amount of fees charged, as adjusted under this subsection, for a fiscal
				year may not exceed the total costs for such fiscal year for the resources
				allocated for the process for the review of abbreviated applications for
				generic new animal drugs.</text>
							</paragraph>
            </subsection>
            <subsection id="H7455F86D37BF4EEF8C517D8FA3B90561">
              <enum>(d)</enum>
              <header>Fee waiver or
				reduction</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall grant a waiver from or a reduction
				of 1 or more fees assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that
				the generic new animal drug is intended solely to provide for a minor use or
				minor species indication.</text>
						</subsection>
            <subsection id="H9EA09270868E4F5CB8254156B12B57BB">
              <enum>(e)</enum>
              <header>Effect of failure To
				pay fees</header>
              <text>An abbreviated application for a generic new animal drug
				submitted by a person subject to fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be considered
				incomplete and shall not be accepted for filing by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> until all fees
				owed by such person have been paid. An investigational submission for a generic
				new animal drug that is submitted by a person subject to fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection
				(a)</cato:entity-ref> shall be considered incomplete and shall not be accepted for review by the
				Secretary until all fees owed by such person have been paid. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may
				discontinue review of any abbreviated application for a generic new animal
				drug, supplemental abbreviated application for a generic new animal drug, or
				investigational submission for a generic new animal drug from a person if such
				person has not submitted for payment all fees owed under this section by 30
				days after the date upon which they are due.</text>
						</subsection>
            <subsection id="HFFEE44A4439C4B0383A878E978DDE23C">
              <enum>(f)</enum>
              <header>Assessment of
				fees</header>
							<paragraph id="H428DA3083B494E5193B948220D9E26D5">
                <enum>(1)</enum>
                <header>Limitation</header>
                <text>Fees
				may not be assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> for a fiscal year beginning after
				fiscal year 2008 unless appropriations for salaries and expenses of the Food
				and Drug Administration for such fiscal year (excluding the amount of fees
				appropriated for such fiscal year) are equal to or greater than the amount of
				appropriations for the salaries and expenses of the Food and Drug
				Administration for the fiscal year 2003 (excluding the amount of fees
				appropriated for such fiscal year) multiplied by the adjustment factor
				applicable to the fiscal year involved.</text>
							</paragraph>
              <paragraph id="HEAA5558D751642FD8CE9C162D0EA038E">
                <enum>(2)</enum>
                <header>Authority</header>
                <text>If
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not assess fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> during any portion of a
				fiscal year because of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref> and if at a later date in such fiscal year
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess such fees, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may assess and collect such
				fees, without any modification in the rate, for abbreviated applications,
				generic new animal drug sponsors, and generic new animal drug products at any
				time in such fiscal year notwithstanding the provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref>
				relating to the date fees are to be paid.</text>
							</paragraph>
            </subsection>
            <subsection id="H6CD3E77F2E59413B8FD33B313E169CA1">
              <enum>(g)</enum>
              <header>Crediting and
				availability of fees</header>
							<paragraph id="H5B934D23F45743F7A8E3839F783F76A2">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>Subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:C" proposed="true">paragraph (2)(C)</cato:entity-ref>, fees authorized under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall be collected and available for obligation only to the
				extent and in the amount provided in advance in appropriations Acts. Such fees
				are authorized to be appropriated to remain available until expended. Such sums
				as may be necessary may be transferred from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>
				salaries and expenses appropriation account without fiscal year limitation to
				such appropriation account for salary and expenses with such fiscal year
				limitation. The sums transferred shall be available solely for the process for
				the review of abbreviated applications for generic new animal drugs.</text>
							</paragraph>
              <paragraph id="HEDC238A16EC44821B8240967679077A8">
                <enum>(2)</enum>
                <header>Collections and
				appropriation acts</header>
								<subparagraph id="HC0763E96CDA14C0BAAC39FA26C47AE86">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The fees authorized by this section—</text>
									<clause id="H900B251EA650403789D6C4B6E19DB793">
                    <enum>(i)</enum>
                    <text>subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:C" proposed="true">subparagraph
				(C)</cato:entity-ref>, shall be collected and available in each fiscal year in an amount not to
				exceed the amount specified in appropriation Acts, or otherwise made available
				for obligation for such fiscal year; and</text>
									</clause>
                  <clause id="HFCCE613B6DCB48C3AA49D82B821E5105">
                    <enum>(ii)</enum>
                    <text>shall be available to
				defray increases in the costs of the resources allocated for the process for
				the review of abbreviated applications for generic new animal drugs (including
				increases in such costs for an additional number of full-time equivalent
				positions in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref> to be engaged in such
				process) over such costs, excluding costs paid from fees collected under this
				section, for fiscal year 2008 multiplied by the adjustment factor.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H0054EF2733664BD3BD7935055974C1DD">
                  <enum>(B)</enum>
                  <header>Compliance</header>
                  <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be considered to have met the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph
				(A)(ii)</cato:entity-ref> in any fiscal year if the costs funded by appropriations and allocated
				for the process for the review of abbreviated applications for generic new
				animal drugs—</text>
									<clause id="HAEE3F86147E648AA977A433A4BE8902B">
                    <enum>(i)</enum>
                    <text>are not more than 3
				percent below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>; or</text>
									</clause>
                  <clause id="H31B3E4E8221F4B50BDDE1DB40953CDE4">
                    <enum>(ii)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="H2F34518399974005AA219C2F38C61847">
                      <enum>(I)</enum>
                      <text>are more than 3 percent
				below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, and fees assessed for the
				fiscal year following the subsequent fiscal year are decreased by the amount in
				excess of 3 percent by which such costs fell below the level specified in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>; and</text>
										</subclause>
                    <subclause changed="added" committee-id="HIF00" id="H95A0AC9977A245E8933814C87A0095AF" indent="up1" reported-display-style="italic">
                      <enum>(II)</enum>
                      <text>such costs are not more
				than 5 percent below the level specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="HDC9175E648F4439F92C7A938F2DAF37E">
                  <enum>(C)</enum>
                  <header>Provision for early
				payments</header>
                  <text>Payment of fees authorized under this section for a
				fiscal year, prior to the due date for such fees, may be accepted by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in accordance with authority provided in advance in a prior year
				appropriations Act.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HC5EA695E22A54BEFA612E3CF29B21493">
                <enum>(3)</enum>
                <header>Authorization of
				appropriations</header>
                <text>
                There are authorized to be appropriated <cato:property xmlns:cato="http://namespaces.cato.org/catoxml" name="purpose">for fees
				under this section</cato:property>—
              </text>
								<subparagraph id="H6CA72CACF8194AB7862667291FC824C7">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(A)</enum>
                  <text>
                      <cato:funds-and-year amount="7328000" year="2014">$7,328,000 for fiscal
				year 2014</cato:funds-and-year>;</text>
                  </cato:entity>
								</subparagraph>
                <subparagraph id="H5F561141FBBF4BFB903B8D6FFBA38451">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(B)</enum>
                  <text>
                      <cato:funds-and-year amount="6944000" year="2015">$6,944,000 for fiscal
				year 2015</cato:funds-and-year>;</text>
                  </cato:entity>
								</subparagraph>
                <subparagraph id="H9DBA9E510B874E12AEF511D6FBB4C464">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(C)</enum>
                  <text>
                      <cato:funds-and-year amount="7429000" year="2016">$7,429,000 for fiscal
				year 2016</cato:funds-and-year>;</text>
                  </cato:entity>
								</subparagraph>
                <subparagraph id="H62B321C7A63C400D98B58632C20E5C45">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(D)</enum>
                  <text>
                      <cato:funds-and-year amount="7936000" year="2017">$7,936,000 for fiscal
				year 2017</cato:funds-and-year>; and</text>
                  </cato:entity>
								</subparagraph>
                <subparagraph id="H7F10882498B64FD4B0A7216E271DF935">
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <enum>(E)</enum>
                  <text>
                      <cato:funds-and-year amount="8467000" year="2018">$8,467,000 for fiscal
				year 2018</cato:funds-and-year>;</text>
                  </cato:entity>
								</subparagraph>
                <continuation-text continuation-text-level="paragraph">as
				adjusted to reflect adjustments in the total fee revenues made under this
				section and changes in the total amounts collected by abbreviated application
				fees, generic new animal drug sponsor fees, and generic new animal drug product
				fees.</continuation-text>
              </paragraph>
              <paragraph id="HBDD0FABEDC614083B49A63D1A9EE20C1">
                <enum>(4)</enum>
                <header>Offset</header>
                <text>If
				the sum of the cumulative amount of fees collected under this section for the
				fiscal years 2014 through 2016 and the amount of fees estimated to be collected
				under this section for fiscal year 2017 exceeds the cumulative amount
				appropriated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:3" proposed="true">paragraph (3)</cato:entity-ref> for the fiscal years 2014 through 2017, the
				excess amount shall be credited to the appropriation account of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
				Drug Administration</cato:entity-ref> as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:1" proposed="true">paragraph (1)</cato:entity-ref>, and shall be subtracted from
				the amount of fees that would otherwise be authorized to be collected under
				this section pursuant to appropriation Acts for fiscal year 2018.</text>
							</paragraph>
            </subsection>
            <subsection id="H6FC4E9BF7F0D48748FBEF456EBDB5450">
              <enum>(h)</enum>
              <header>Collection of unpaid
				fees</header>
              <text>In any case where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not receive payment of
				a fee assessed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref> within 30 days after it is due, such fee
				shall be treated as a claim of the United States Government subject to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States Code</cato:entity-ref>.</text>
						</subsection>
            <subsection id="H53305811A0E04420BEA7A08CD880A53C">
              <enum>(i)</enum>
              <header>Written requests for
				waivers, reductions, and refunds</header>
              <text>To qualify for consideration for
				a waiver or reduction under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:d" proposed="true">subsection (d)</cato:entity-ref>, or for a refund of any fee
				collected in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:a" proposed="true">subsection (a)</cato:entity-ref>, a person shall submit to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a written request for such waiver, reduction, or refund not later
				than 180 days after such fee is due.</text>
						</subsection>
            <subsection id="HED9A15E7E363462D9ADD27DB179EDFD8">
              <enum>(j)</enum>
              <header>Construction</header>
              <text>This
				section may not be construed to require that the number of full-time equivalent
				positions in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref>, for officers,
				employees, and advisory committees not engaged in the process of the review of
				abbreviated applications for generic new animal drugs, be reduced to offset the
				number of officers, employees, and advisory committees so engaged.</text>
						</subsection>
            <subsection id="H6C92FD26FC4B4377A900D92366D6A577">
              <enum>(k)</enum>
              <header>Definitions</header>
              <text>In
				this section and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742" proposed="true">section 742</cato:entity-ref>:</text>
							<paragraph id="HC4212EAC87344501A23ABA46434BEAE1">
                <enum>(1)</enum>
                <header>Abbreviated application
				for a generic new animal drug</header>
                <text>The terms <quote>abbreviated
				application for a generic new animal drug</quote> and <quote>abbreviated
				application</quote> mean an abbreviated application for the approval of any
				generic new animal drug submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:b/p:2">section 512(b)(2)</cato:entity-ref>. Such term does not
				include a supplemental abbreviated application for a generic new animal
				drug.</text>
							</paragraph>
              <paragraph id="H05CB296EE9384D98B81E20BA3F9C0A97">
                <enum>(2)</enum>
                <header>Adjustment
				factor</header>
                <text>The term <term>adjustment factor</term> applicable to a
				fiscal year is the Consumer Price Index for all urban consumers (all items;
				United States city average) for October of the preceding fiscal year divided
				by—</text>
								<subparagraph id="HF666AF2CF1E141DC868A43A9B0DB90B3">
                  <enum>(A)</enum>
                  <text>for purposes of
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:f/p:1" proposed="true">subsection (f)(1)</cato:entity-ref>, such Index for October 2002; and</text>
								</subparagraph>
                <subparagraph id="H9A2DECDEF28A46149FCDB1F6DC9D7752">
                  <enum>(B)</enum>
                  <text>for purposes of
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741/ss:g/p:2/sp:A/cl:ii" proposed="true">subsection (g)(2)(A)(ii)</cato:entity-ref>, such Index for October 2007.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HA7CDC64A0D70448A8FDF60B5CC9C79F7">
                <enum>(3)</enum>
                <header>Costs of resources
				allocated for the process for the review of abbreviated applications for
				generic new animal drugs</header>
                <text>The term <term>costs of resources
				allocated for the process for the review of abbreviated applications for
				generic new animal drugs</term> means the expenses in connection with the
				process for the review of abbreviated applications for generic new animal drugs
				for—</text>
								<subparagraph id="HA4C5C10B6FB347FD9218FC0BBD561DE6">
                  <enum>(A)</enum>
                  <text>officers and employees of
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, contractors of the Food and Drug
				Administration, advisory committees consulted with respect to the review of
				specific abbreviated applications, supplemental abbreviated applications, or
				investigational submissions, and costs related to such officers, employees,
				committees, and contractors, including costs for travel, education, and
				recruitment and other personnel activities;</text>
								</subparagraph>
                <subparagraph id="H0ADFE85E78B542389B186AE1DC4A941F">
                  <enum>(B)</enum>
                  <text>management of
				information, and the acquisition, maintenance, and repair of computer
				resources;</text>
								</subparagraph>
                <subparagraph id="H6AD3F95943B643DA8DAF154637716464">
                  <enum>(C)</enum>
                  <text>leasing, maintenance,
				renovation, and repair of facilities and acquisition, maintenance, and repair
				of fixtures, furniture, scientific equipment, and other necessary materials and
				supplies; and</text>
								</subparagraph>
                <subparagraph id="H46BCF2D2B5DC470ABBE22B9C0A40BC87">
                  <enum>(D)</enum>
                  <text>collecting fees under
				this section and accounting for resources allocated for the review of
				abbreviated applications, supplemental abbreviated applications, and
				investigational submissions.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HC08A320770374791A0C552624B10640C">
                <enum>(4)</enum>
                <header>Final dosage
				form</header>
                <text>The term <term>final dosage form</term> means, with respect
				to a generic new animal drug product, a finished dosage form which is approved
				for administration to an animal without substantial further manufacturing. Such
				term includes generic new animal drug products intended for mixing in animal
				feeds.</text>
							</paragraph>
              <paragraph id="H02B19E83A77C4CFDAB2C77FFF9423DF1">
                <enum>(5)</enum>
                <header>Generic new animal
				drug</header>
                <text>The term <term>generic new animal drug</term> means a new
				animal drug that is the subject of an abbreviated application.</text>
							</paragraph>
              <paragraph id="H5A4B8A06A4514E4D8E21B11EF810A7A6">
                <enum>(6)</enum>
                <header>Generic new animal drug
				product</header>
                <text>The term <term>generic new animal drug product</term>
				means each specific strength or potency of a particular active ingredient or
				ingredients in final dosage form marketed by a particular manufacturer or
				distributor, which is uniquely identified by the labeler code and product code
				portions of the national drug code, and for which an abbreviated application
				for a generic new animal drug or a supplemental abbreviated application has
				been approved.</text>
							</paragraph>
              <paragraph id="HAFB2A1A674664BDC9E7F0BF927F49AE9">
                <enum>(7)</enum>
                <header>Generic new animal drug
				sponsor</header>
                <text>The term <term>generic new animal drug sponsor</term>
				means either an applicant named in an abbreviated application for a generic new
				animal drug that has not been withdrawn by the applicant and for which approval
				has not been withdrawn by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, or a person who has submitted an
				investigational submission for a generic new animal drug that has not been
				terminated or otherwise rendered inactive by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="HF39DC0FC19E74EA19630D2FECC5754AA">
                <enum>(8)</enum>
                <header>Investigational
				submission for a generic new animal drug</header>
                <text>The terms
				<term>investigational submission for a generic new animal drug</term> and
				<quote>investigational submission</quote> mean—</text>
								<subparagraph id="HE18A7834F3D8451ABF4BC745F51126E9">
                  <enum>(A)</enum>
                  <text>the filing of a claim for
				an investigational exemption under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:j">section 512(j)</cato:entity-ref> for a generic new animal drug
				intended to be the subject of an abbreviated application or a supplemental
				abbreviated application; or</text>
								</subparagraph>
                <subparagraph id="H6954C49B066F4EEA9C8790D1D0C238BA">
                  <enum>(B)</enum>
                  <text>the submission of
				information for the purpose of enabling the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to evaluate the safety or
				effectiveness of a generic new animal drug in the event of the filing of an
				abbreviated application or supplemental abbreviated application for such
				drug.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HB686E7A08B8F4CD18271E57A19939BC7">
                <enum>(9)</enum>
                <header>Person</header>
                <text>The
				term <term>person</term> includes an affiliate thereof (as such term is defined
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:11">section 735(11)</cato:entity-ref>).</text>
							</paragraph>
              <paragraph id="HFA819836FB384A67B3E679BB4F3D0F0F">
                <enum>(10)</enum>
                <header>Process for the review
				of abbreviated applications for generic new animal drugs</header>
                <text>The term
				<term>process for the review of abbreviated applications for generic new animal
				drugs</term> means the following activities of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> with respect to
				the review of abbreviated applications, supplemental abbreviated applications,
				and investigational submissions:</text>
								<subparagraph id="HF8FB9B03AA124DF79A79087452F960DD">
                  <enum>(A)</enum>
                  <text>The activities necessary
				for the review of abbreviated applications, supplemental abbreviated
				applications, and investigational submissions.</text>
								</subparagraph>
                <subparagraph id="HBF2514551E4A412997930F74CB2D4A29">
                  <enum>(B)</enum>
                  <text>The issuance of action
				letters which approve abbreviated applications or supplemental abbreviated
				applications or which set forth in detail the specific deficiencies in
				abbreviated applications, supplemental abbreviated applications, or
				investigational submissions and, where appropriate, the actions necessary to
				place such applications, supplemental applications, or submissions in condition
				for approval.</text>
								</subparagraph>
                <subparagraph id="HFB36B6EA6A974AEEAA9CECCEC8CCDC14">
                  <enum>(C)</enum>
                  <text>The inspection of generic
				new animal drug establishments and other facilities undertaken as part of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> review of pending abbreviated applications, supplemental
				abbreviated applications, and investigational submissions.</text>
								</subparagraph>
                <subparagraph id="H03DB435A2EBE4D7DAD4C6E851849B4CC">
                  <enum>(D)</enum>
                  <text>Monitoring of research
				conducted in connection with the review of abbreviated applications,
				supplemental abbreviated applications, and investigational submissions.</text>
								</subparagraph>
                <subparagraph id="H3CD3AB565E7149E9B3B78AB8F5F98FBC">
                  <enum>(E)</enum>
                  <text>The development of
				regulations and policy related to the review of abbreviated applications,
				supplemental abbreviated applications, and investigational submissions.</text>
								</subparagraph>
                <subparagraph id="HA4A5C4210A484302B0CF83D49A3A61AB">
                  <enum>(F)</enum>
                  <text>Development of standards
				for products subject to review.</text>
								</subparagraph>
                <subparagraph id="H0149F54A52E64638B74FBCB2D0C6D972">
                  <enum>(G)</enum>
                  <text>Meetings between the
				agency and the generic new animal drug sponsor.</text>
								</subparagraph>
                <subparagraph id="HA50AC19898A844FEBD572C4082529C15">
                  <enum>(H)</enum>
                  <text>Review of advertising and
				labeling prior to approval of an abbreviated application or supplemental
				abbreviated application, but not after such application has been
				approved.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H76AD418EF2FD4530AF0C45637EC895DD">
                <enum>(11)</enum>
                <header>Supplemental
				abbreviated application for generic new animal drug</header>
                <text>The terms
				<quote>supplemental abbreviated application for a generic new animal
				drug</quote> and <quote>supplemental abbreviated application</quote> mean a
				request to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to approve a change in an approved abbreviated
				application.</text>
							</paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section id="HA2992BBB203C48F486BDBDF43BF9E1A0">
        <enum>203.</enum>
        <header>Reauthorization;
			 reporting requirements</header>
        <text display-inline="no-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742">Section
			 742 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-22">
              <cato:entity-ref entity-type="uscode" value="usc/21/379j–22">21 U.S.C. 379j–22</cato:entity-ref>
            </external-xref>)</cato:entity> is amended
			 to read as follows:</text>
				<quoted-block changed="added" committee-id="HIF00" display-inline="no-display-inline" id="H0A02A82E9C974F99AF82F4B85CEA7F49" reported-display-style="italic" style="OLC">
					<section id="H8DF60BA7FDDF4F5A98CEDC84C071F5E8">
            <enum>742.</enum>
            <header>Reauthorization;
				reporting requirements</header>
						<subsection id="H28884148BDEF4D508FF64912D1A6F312">
              <enum>(a)</enum>
              <header>Performance
				reports</header>
              <text>Beginning with fiscal year 2014, not later
				than 120 days after the end of each fiscal year during which fees are collected
				under this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall prepare and submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on
				Health, Education, Labor, and Pensions of the Senate</cato:entity-ref>, and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on
				Energy and Commerce of the House of Representatives</cato:entity-ref> a report concerning the
				progress of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> in achieving the goals identified
				in the letters described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Generic Drug User Fee Amendments of 2013/s:201/ss:b" proposed="true">section 201(b) of the Animal Generic Drug User Fee
				Amendments of 2013</cato:entity-ref> toward expediting the generic new animal drug development
				process and the review of abbreviated applications for generic new animal
				drugs, supplemental abbreviated applications for generic new animal drugs, and
				investigational submissions for generic new animal drugs during such fiscal
				year.</text>
						</subsection>
            <subsection id="H1C05DF7CE546424386C70C7B2CE78189">
              <enum>(b)</enum>
              <header>Fiscal
				report</header>
              <text>Beginning with fiscal year 2014, not later than 120 days
				after the end of each fiscal year during which fees are collected under this
				part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall prepare and submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health,
				Education, Labor, and Pensions of the Senate</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and
				Commerce of the House of Representatives</cato:entity-ref> a report on the implementation of the
				authority for such fees during such fiscal year and the use, by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
				Drug Administration</cato:entity-ref>, of the fees collected during such fiscal year for which
				the report is made.</text>
						</subsection>
            <subsection id="HF9A8B7B7257E434286B5BF20F75B8D38">
              <enum>(c)</enum>
              <header>Public
				availability</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make the reports required under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:a" proposed="true">subsections (a)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:b" proposed="true">(b)</cato:entity-ref> available to the public on the Internet Web site of the
				Food and Drug Administration.</text>
						</subsection>
            <subsection id="HA5EE00D3911E431A83D2630447A807AB">
              <enum>(d)</enum>
              <header>Reauthorization</header>
							<paragraph id="H00F0E08CC8BD4558AD80190BB89D0C84">
                <enum>(1)</enum>
                <header>Consultation</header>
                <text>In
				developing recommendations to present to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> with respect to the goals,
				and plans for meeting the goals, for the process for the review of abbreviated
				applications for generic new animal drugs for the first 5 fiscal years after
				fiscal year 2018, and for the reauthorization of this part for such fiscal
				years, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consult with—</text>
								<subparagraph id="HAB2231A05FBC4423A90FD16342332C93">
                  <enum>(A)</enum>
                  <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy
				and Commerce of the House of Representatives</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="H6E7C9CAB02A84CE5A8766B1300D8CFF4">
                  <enum>(B)</enum>
                  <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health,
				Education, Labor, and Pensions of the Senate</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="H6D69F3F5745E4618B6277E4399B2058B">
                  <enum>(C)</enum>
                  <text>scientific and academic
				experts;</text>
								</subparagraph>
                <subparagraph id="HD667E9A42E174D01B690A7C06AF4CA1C">
                  <enum>(D)</enum>
                  <text>veterinary
				professionals;</text>
								</subparagraph>
                <subparagraph id="H3A67D8CC408244C8B19B5635CFBEE1F9">
                  <enum>(E)</enum>
                  <text>representatives of
				patient and consumer advocacy groups; and</text>
								</subparagraph>
                <subparagraph id="HD4628CC71CB04CA49812D17A75314EE6">
                  <enum>(F)</enum>
                  <text>the regulated
				industry.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HB061671AC8A045AB8EE64AC0318006F8">
                <enum>(2)</enum>
                <header>Prior public
				input</header>
                <text>Prior to beginning negotiations with the regulated industry
				on the reauthorization of this part, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<subparagraph id="H71AFCC31CEC44D6484A8324EF5CA3DAC">
                  <enum>(A)</enum>
                  <text>publish a notice in the
				Federal Register requesting public input on the reauthorization;</text>
								</subparagraph>
                <subparagraph id="H2905BD1AA5BD4EBC8283C38AA8E241C1">
                  <enum>(B)</enum>
                  <text>hold a public meeting at
				which the public may present its views on the reauthorization, including
				specific suggestions for changes to the goals referred to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:a" proposed="true">subsection
				(a)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="H4D0954B6F6DA4618810799F319B646AF">
                  <enum>(C)</enum>
                  <text>provide a period of 30
				days after the public meeting to obtain written comments from the public
				suggesting changes to this part; and</text>
								</subparagraph>
                <subparagraph id="H822FCDFD9FA84F1B8499BE2E650B935D">
                  <enum>(D)</enum>
                  <text>publish the comments on
				the Food and Drug Administration’s Internet Web site.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H717343B8918E4F878146A8A7409B92FA">
                <enum>(3)</enum>
                <header>Periodic
				consultation</header>
                <text>Not less frequently than once every 4 months during
				negotiations with the regulated industry, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall hold discussions
				with representatives of veterinary, patient, and consumer advocacy groups to
				continue discussions of their views on the reauthorization and their
				suggestions for changes to this part as expressed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:2" proposed="true">paragraph (2)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H6F5798A53DAC4CBAA3E8A87D95E35BF8">
                <enum>(4)</enum>
                <header>Public review of
				recommendations</header>
                <text>After negotiations with the regulated industry,
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<subparagraph id="HCE6990599D484DE885C6EB10C6360401">
                  <enum>(A)</enum>
                  <text>present the
				recommendations developed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref> to the congressional committees
				specified in such paragraph;</text>
								</subparagraph>
                <subparagraph id="H77859CB47142405BA398DF9578D67599">
                  <enum>(B)</enum>
                  <text>publish such
				recommendations in the Federal Register;</text>
								</subparagraph>
                <subparagraph id="H394B9FB0F924454B99C7A068E7201207">
                  <enum>(C)</enum>
                  <text>provide for a period of
				30 days for the public to provide written comments on such
				recommendations;</text>
								</subparagraph>
                <subparagraph id="H189457F059D9451EA61CB6DDEA380E42">
                  <enum>(D)</enum>
                  <text>hold a meeting at which
				the public may present its views on such recommendations; and</text>
								</subparagraph>
                <subparagraph id="H8EE0350C342545288B8774409C6B5748">
                  <enum>(E)</enum>
                  <text>after consideration of
				such public views and comments, revise such recommendations as
				necessary.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HD1865FEB3CA0406E86066F3BBC007E99">
                <enum>(5)</enum>
                <header>Transmittal of
				recommendations</header>
                <text>Not later than January 15, 2018, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall transmit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> the revised recommendations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:4" proposed="true">paragraph (4)</cato:entity-ref>, a
				summary of the views and comments received under such paragraph, and any
				changes made to the recommendations in response to such views and
				comments.</text>
							</paragraph>
              <paragraph id="HEDF9BFDEC7564F94A5D82149C43EE982">
                <enum>(6)</enum>
                <header>Minutes of negotiation
				meetings</header>
								<subparagraph id="H246FC885DA654B329ADB64685190FBCC">
                  <enum>(A)</enum>
                  <header>Public
				availability</header>
                  <text>Before presenting the recommendations developed
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:1..5" proposed="true">paragraphs (1) through (5)</cato:entity-ref> to Congress, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make publicly
				available, on the Internet Web site of the Food and Drug Administration,
				minutes of all negotiation meetings conducted under this subsection between the
				Food and Drug Administration and the regulated industry.</text>
								</subparagraph>
                <subparagraph id="H560A7610AE0244CCB4C19ABBA36C9653">
                  <enum>(B)</enum>
                  <header>Content</header>
                  <text>The
				minutes described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742/ss:d/p:6/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall summarize any substantive
				proposal made by any party to the negotiations as well as significant
				controversies or differences of opinion during the negotiations and their
				resolution.</text>
								</subparagraph>
              </paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</section>
      <section id="H83E3CC685FA74B32A47F803CED686D9C">
        <enum>204.</enum>
        <header>Savings
			 clause</header>
        <text display-inline="no-display-inline">Notwithstanding the
			 amendments made by this title, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:5">part 5 of subchapter C of chapter VII of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as in effect on the day before the date
			 of enactment of this title, shall continue to be in effect with respect to
			 abbreviated applications for a generic new animal drug and supplemental
			 abbreviated applications for a generic new animal drug (as defined in such part
			 as of such day) that on or after October 1, 2008, but before October 1, 2013,
			 were accepted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> for filing with respect to
			 assessing and collecting any fee required by such part for a fiscal year prior
			 to fiscal year 2014.</text>
			</section>
      <section id="HC2BA9599B1D34A349F78F644EFB91691">
        <enum>205.</enum>
        <header>Effective
			 date</header>
        <text display-inline="no-display-inline">The amendments made by
			 this title shall take effect on October 1, 2013, or the date of enactment of
			 this title, whichever is later, except that fees under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C/pt:5">part 5 of subchapter C
			 of chapter VII of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as amended by this
			 title, shall be assessed for all abbreviated applications for a generic new
			 animal drug and supplemental abbreviated applications for a generic new animal
			 drug received on or after October 1, 2013, regardless of the date of enactment
			 of this title.</text>
			</section>
      <section id="HDD72B01819D14FAB84BD9832B4014201">
        <enum>206.</enum>
        <header>Sunset dates</header>
				<subsection id="HCFF03F69BC6042D8A147B0395C50478B">
          <enum>(a)</enum>
          <header>Authorization</header>
          <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:741" proposed="true">Section
			 741 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">
                <cato:entity-ref entity-type="uscode" value="usc/21/379j–21" proposed="true">21 U.S.C. 379j–21</cato:entity-ref>
              </external-xref>)</cato:entity> shall cease
			 to be effective October 1, 2018.</text>
				</subsection>
        <subsection id="H091DC25AA0C24B3097FDED366CB82EC4">
          <enum>(b)</enum>
          <header>Reporting
			 requirements</header>
          <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:742" proposed="true">Section 742 of the Federal Food, Drug, and Cosmetic
			 Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-22">
                <cato:entity-ref entity-type="uscode" value="usc/21/379j–22" proposed="true">21 U.S.C. 379j–22</cato:entity-ref>
              </external-xref>)</cato:entity> shall cease to be effective January 31, 2019.</text>
				</subsection>
        <subsection commented="no" id="HF884CD85657B44A59382E966BA6ACC78">
          <enum>(c)</enum>
          <header>Previous sunset
			 provision</header>
					<paragraph commented="no" id="H220705ED3D394539AF25F58025E20772">
            <enum>(1)</enum>
            <header>In
			 general</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Animal Generic Drug User Fee Act of 2008/s:204">Section 204 of the Animal Generic Drug User Fee Act of
			 2008</cato:entity-ref> (<external-xref legal-doc="public-law" parsable-cite="pl/110/316">
                  <cato:entity-ref entity-type="public-law" value="public-law/110/316">Public Law 110–316</cato:entity-ref>
                </external-xref>)</cato:entity> is repealed.</text>
					</paragraph>
          <paragraph commented="no" id="HE22B1C4374324AD998965B9C304B511F">
            <enum>(2)</enum>
            <header>Conforming
			 amendment</header>
            <text display-inline="yes-display-inline">
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="public-law" value="public-law/110/316">Public Law 110–316</cato:entity-ref>
			 (<cato:entity-ref entity-type="statute-at-large" value="statute-at-large/122/3509">122 Stat. 3509</cato:entity-ref>)</cato:entity> is amended in the table of contents in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Generic Drug User Fee Act of 2008/s:1">section 1</cato:entity-ref>, by striking
			 the item relating to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Animal Generic Drug User Fee Act of 2008/s:204">section 204</cato:entity-ref>.</text>
					</paragraph>
        </subsection>
      </section>
    </title>
  </legis-body>
  <official-title-amendment>Amend the title so as to read:
	 <quote>A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize
	 user fee programs relating to new animal drugs and generic new animal
	 drugs.</quote>.</official-title-amendment>
	<endorsement display="yes">
		<action-date>August 2, 2013</action-date>
		<action-desc>Reported with amendments, committed to the Committee of the
		  Whole House on the State of the Union, and ordered to be printed</action-desc>
	</endorsement>
</bill>
</doc>